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Abstract
Pyronaridine was synthesized in 1970 at the Institute of Chinese Parasitic Disease and has been used in China for
over 30 years for the treatment of malaria. Pyronaridine has high potency against Plasmodium falciparum, including
chloroquine-resistant strains. Studies in various animal models have shown pyronaridine to be effective against
strains resistant to other anti-malarials, including chloroquine. Resistance to pyronaridine appears to emerge slowly
and is further retarded when pyronaridine is used in combination with other anti-malarials, in particular, artesunate.
Pyronaridine toxicity is generally less than that of chloroquine, though evidence of embryotoxicity in rodents
suggests use with caution in pregnancy. Clinical pharmacokinetic data for pyronaridine indicates an elimination T1/2
of 13.2 and 9.6 days, respectively, in adults and children with acute uncomplicated falciparum and vivax malaria in
artemisinin-combination therapy. Clinical data for mono or combined pyronaridine therapy show excellent anti-
malarial effects against P. falciparum and studies of combination therapy also show promise against Plasmodium
vivax. Pyronaridine has been developed as a fixed dose combination therapy, in a 3:1 ratio, with artesunate for the
treatment of acute uncomplicated P. falciparum malaria and blood stage P. vivax malaria with the name of
PyramaxW and has received Positive Opinion by European Medicines Agency under the Article 58 procedure.
Keywords: Pyronaridine, Plasmodium falciparum, Plasmodium vivax, Review, Artemisinin containing compound,
Anti-malarial therapy
Background
Pyronaridine (4-[(7-chloro-2-methoxybenzo[b][1,5]
naphthyridin-10-yl)amino]-2,6-bis[(pyrrolidin-1-yl)methyl]
phenol) [Recommended INN: List 59 41: WHO Drug In-
formation, Vol. 22, No. 1, 2008] is a benzonaphthyridine
derivative first synthesized in 1970 at the Institute of
Chinese Parasitic Disease, Chinese Academy of Preventa-
tive Medicine [1,2]. Pyronaridine also referred to as
‘7351’ and MalaridineW has been used in China for the
treatment of malaria as a single agent for the past
30 years.
More recently, interest has been renewed in pyronari-
dine as a possible partner for use in artemisinin-based
combination therapy (ACT) for malaria treatment. In-
deed, its limited use outside China suggests that resist-
ance will be slow to emerge when used in ACT and
pyronaridine is currently under investigation as a fixed-
dose combination administered in a 3:1 ratio with arte-
sunate for the treatment of uncomplicated Plasmodium
falciparum and blood stage Plasmodium vivax malaria.
This review examines the in vitro activity, anti-malarial
effect, toxicology, pharmacokinetic and clinical data on
pyronaridine.
Chemistry, presentation and properties
The pyronaridine nucleus is based on mepacrine (a 9-
aminoacridine) with the addition of an amodiaquine-like
side chain (Figure 1) [3,4]. The drug is administered as
pyronaridine tetraphosphate (56.89% base), a yellow,
odourless powder with a bitter taste [3]. The drug was
produced in China as tablets for oral use, as an inject-
able liquid for intramuscular (IM) administration and
has also been administered intravenously (IV) [3,5]. Al-
most all published clinical trials to date used the Chinese
enteric-coated tablet formulation with 175 mg of the tet-
raphosphate, equal to 100 mg base, with dosages
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calculated as the free base. The Chinese also developed a
capsule formulation available as 100 mg and 50 mg free
base. A capsule fixed-dose formulation of pyronaridine
tetraphosphate plus artesunate (3:1 ratio) has been
reported by University Sains, Malaysia with pyronaridine
dosages based on the tetraphosphate [6].
Pyronaridine free base is ‘very sparingly’ soluble in
water, whereas the tetraphosphate salt is ‘sparingly’ sol-
uble in water (1.46%), aiding oral absorption [7]. The
greater hydrophobicity index (Rm 0.872) of the salt con-
firms the higher aqueous solubility versus the base (Rm
0.773). Pyronaridine has been found to be highly
lipophilic at pH 7.4 (logD 0.34); lipophilicity was
reduced at pH 5 [8]. The base is more liposoluble than
the salt [7].
In vitro studies
Pyronaridine has potent in vitro activity against P. falcip-
arum strains [9-13] and clinical isolates [9,10,12,14-17]
including those that are resistant to other anitmalarials.
The mechanism(s) by which pyronaridine acts as an
antimalarial has been examined. Initial studies demon-
strated that pyronairidne interfered with the digestive
system of P. falciparum and Plasmodium berghei [18].
Subsequently it was reported that pyronaridine inhibited
production of, and formed complexes with, β-haematin
to enhance haematin-induced human blood cell lysis
[19,20]. Pyronaridine also inhibits glutathione-dependent
haem degredation [19,21].
In vitro combination of pyronaridine with other antimal-
arial agents including artesunate or DHA has shown either
additiveeffects[22]orweakantagonism[11,23,24],dependent
on the experimental model employed.
Mechanism of action
Early studies indicated that pyronaridine appeared to
interfere with the food vacuole of the parasite [25,26]. In
erythrocytic P. falciparum and P. berghei cultured
in vitro in human erythrocytes, pyronaridine induced
modifications to the food vacuoles followed by the rapid
formation of multilameliate whorls in the pellicular com-
plexes of trophozoites [18]. Similarly, ultrastructural
analysis of P. falciparum after pyronaridine treatment of
infected primates (Aotus trivirgatus) showed the earliest
and most distinct effect of therapy was on the parasite
food vacuole of late trophozoites and schizonts; specific-
ally, undigested endocytic vesicles surrounded by a sin-
gle membrane in the vascular space were observed [27].
Subsequent in vitro studies have reported that pyro-
naridine targets haematin formation [19,20,28]. Pyronar-
idine inhibited β-haematin production with an IC50
similar to that of chloroquine (0.125 μM) and formed
complexes with β-haematin with a 1:2 stoichiometry to
enhance haematin-induced human blood cell lysis. 10
μM of pyronaridine was needed for complete lysis, ap-
proximately 1/100 of the concentration needed with
chloroquine [29]. However, there was no clear evidence
for antagonism between pyronaridine and other anti-
malarials that target haematin formation (chloroquine,
mefloquine or quinine) [29]. Pyronaridine has also been
shown to inhibit glutathione-dependent haem degreda-
tion [19,21].
Another study reported that pyronaridine inhibited the
decatenation activity of P. falciparum DNA topoisomer-
ase II [30]. However, an assay detecting the presence of
protein−DNA complexes within parasite cells found no
Pyronaridine (C29H32N5O2Cl) 
 Mepacrine 
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Figure 1 Comparative activity of pyronaridine against
chloroquine-susceptible and -resistant P. falciparum field
isolates from SE Asia and Africa.
Croft et al. Malaria Journal 2012, 11:270 Page 2 of 28
http://www.malariajournal.com/content/11/1/270
inhibitory effect of pyronaridine against P. falciparum
topoisomerase II activity in situ [31].
In vitro activity against Plasmodium falciparum
Using various techniques, there is a great deal of evi-
dence that pyronaridine has potent in vitro activity
against P. falciparum clinical isolates (Additional file 1)
[9,10,14-17], and strains (Additional file 2) [9-13,32], in-
cluding those resistant to other anti-malarials.
Pyronaridine activity against erythrocytic P. falciparum
is greatest for the ring-form stage (ED50 8.3 [95% CI 8.1
−8.4] nM), followed by schizonts (11.6 [11.4−11.9] nM)
then trophozoites (14.0 [13.4−14.7] nM) [33]. Pyronari-
dine was more active against all of these stages than
chloroquine: ED50s for ring-forms, schizonts and tropho-
zoites were 24.5 (24.3−24.8), 64.9 (58.1−72.4) and 34.0
(32.4−35.6) nM, respectively [33].
Pyronaridine retains high activity against chloroquine
resistant strains. For example, an ex vivo study of serum
from Saimiri monkeys given 30 mg/kg pyronaridine gave
an IC50 of 7 ± 5 ng/ml and an IC90 of 11 ± 9 ng/ml
against the multi-drug resistant K1 P. falciparum strain
[34]. In comparison the IC50 for chloroquine was 107 ±
36 ng/ml and the IC90 152 ± 46 ng/ml, and values for
amodiaquine were 9 ± 3 ng/ml and 10 ± 4 ng/ml, re-
spectively. Pyronaridine activity was notably more pro-
longed than either chloroquine or amodiaquine in this
study [34].
Moreover, the maximal effect of pyronaridine appears
to be unaffected by chloroquine resistance, pyronaridine
Emax (% inhibition) was 95−100% against three
chloroquine-sensitive strains, comparable to the max-
imal inhibitory activity of artemisinin (97−100%), dihy-
droartemisinin (96−99%) and artemether (87−97%).
Against a chloroquine-resistant strain (D7, Tanzania)
pyronaridine Emax was 96 ± 7% compared with 84−91%
for the artemisinins [13].
Cross resistance with chloroquine and other anti-
malarials
The activity of pyronaridine against chloroquine sensi-
tive and resistant field isolates and strains is shown in
Additional files 1 and 2 [9-17,32]. Structurally related
compounds to pyronaridine, such as amodiaquine,
demonstrated similar activity against chloroquine sensi-
tive and resistant strains [17]. Note that the cut-off value
for in vitro reduced susceptibility to pyronaridine has
not been validated and all cut-offs reported in the litera-
ture are arbitrary [14,16].
Early studies of isolates from Hainan (FCC-4/HN,
FCC-5/HN), Anhui (FCC101/AH), and Jiangsu (FCC-
102/JS) provinces in China and from Cambodia (Camb-
I) showed no evidence of cross resistance between pyro-
naridine and chloroquine: the pyronaridine IC50 was
12.4−22.6 nM against chloroquine-sensitive strains ver-
sus 10.9−17.6 nM against chloroquine-resistant strains
[35]. Pyronaridine was also significantly more active
against the K1 (Thailand) chloroquine-resistant strain
than against a chloroquine-sensitive one (F32 [Tanza-
nia]) (P < 0.05) [36].
In one study of field isolates from eastern and north-
ern Thailand, no cross resistance was found between
pyronaridine and chloroquine, quinine, amodiaquine,
pyrimethamine or mefloquine (Additional file 1), though
there was some degree of cross resistance between pyro-
naridine and chloroquine for reference strains (Add-
itional file 2) [9]. Another study conducted in Thailand
found a statistically significant correlation between
chloroquine and pyronaridine IC50 and IC90 (r= 0.447,
P= 0.0006 and r= 0.477, P= 0.0002, respectively) [37].
However, a statistically significant result (P < 0.05) can
often been seen when comparing drug activities against
large numbers of isolates; when looking at correlations,
an r value of > 0.7−0.8 or r2 of > 0.5 is more suggestive of
cross resistance. Considering this, the correlations be-
tween pyronaridine and chloroquine IC50 and IC90 in
this study were weak. In a study of the uptake of [3 H]
pyronaridine by P. falciparum-infected erythrocytes, up-
take was similar for both chloroquine-sensitive and
chloroquine-resistant strains (T9.96 and K1), being five
times less for the comparator chloroquine [38].
An analysis of African field isolates found no correl-
ation between the in vitro activity of pyronaridine and
chloroquine or monodesethylamodiaquine, though there
was a correlation with amopyroquine (Additional file 1)
[10]. Surveillance studies of 67 P. falciparum infections
imported from East and West Africa into Italy showed
33.3% pyronaridine resistance and a weak correlation
with chloroquine resistance (r= 0.38, P < 0.05) [39]. Sur-
prisingly, chloroquine resistance was only 14% in these
strains [39]. The relevance of these findings is unknown
as they do not appear to reflect the situation reported
for transmission zones.
Data are also available from individual countries in Af-
rica. A study in Cameroon found no evidence of cross
resistance between pyronaridine and chloroquine (Add-
itional file 1) [17]. Similarly, a recent study in Cameroon
found high levels of susceptibility to pyronaridine
(89.5%) in all isolates, including chloroquine-resistant
isolates [40]. In contrast, field isolates from Senegal
showed a weak correlation between pyronaridine and
chloroquine in vitro activity (r= 0.44, P < 0.001) (Add-
itional file 1) [16]. Pyronaridine activity was significantly
decreased for chloroquine-resistant (4.9 nM) versus sen-
sitive strains (2.9 nM, P < 0.002), though pyronaridine
was around 12-fold and 50-fold more active than
chloroquine against these strains, respectively [15,16].
Similarly, in field isolates from Gabon there was a strong
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correlation between pyronaridine in vitro activity and
that of amodiaquine and halofantrine (r= 0.74, r= 0.71,
respectively, P < 0.001 for both) with a weaker correl-
ation for quinine, and chloroquine (r= 0.60, r= 0.51, re-
spectively, P < 0.001 for both) [14]. The IC50 for
pyronaridine was ≤ 4.3 nM in all strains tested (n = 59)
(Additional file 1) [14]. Pyronaridine and chloroquine
IC50 against 38 clinical isolates from Mogadishu, Somalia
also showed a significant but weak correlation
(r= 0.5733, P= 0.001) [41].
A study of 12 reference strains/clones from various
regions found a correlation between pyronaridine and
chloroquine at the IC50 level (r= 0.63, P= 0.03), but not
at the IC99 level (r= 0.54, P= 0.07) [32]. Contrastingly,
the opposite was found for pyronaridine and quinine
(IC50 r= 0.48, P= 0.12; IC90 r= 0.71, P= 0.01) [32]. There
was no cross resistance with mefloquine, but there was
with mepacrine and amodiaquine at the IC50 (r= 0.87,
P= 0.01; r= 0.95, P= 0.01, respectively) and IC99
(r= 0.85, P= 0.01; r= 0.77, P= 0.01, respectively) (Add-
itional file 2) [32].
Thus, the relationship between pyronaridine and
chloroquine susceptibility in P. falciparum appears to be
more complex than simple cross resistance and may vary
regionally. However, it is certain that pyronaridine is far
more active than chloroquine against P. falciparum
in vitro and retains high activity against the majority of
chloroquine-resistant field isolates (Additional file 1)
[9,10,14-17], and reference strains (Additional file 2) [9-
13,32].
Combination therapy
Conflicting data exists concerning the in vitro effect of pyr-
onaridine in combination with other anti-malarials. In one
study, there was synergy between pyronaridine and prima-
quine, an additive effect with 4-aminoquinolines and weak
antagonism with antifolates, amino alcohols and dihydroar-
temisinin [24]. Further studies also found weak antagonism
between pyronaridine and dihydroartemisinin or artesunate
[11,23]. However, both additive and synergistic effects be-
tween artemisinin and pyronaridine has also been reported
[22]. These differences are probably methodological and
in vivo studies indicate high efficacy and a synergistic effect
between pyronaridine and artemisinin or artesunate against
pathogens with in vitro resistance to these agents [11,42].
Mechanism and development of resistance
The mechanism by which resistance to pyronaridine
develops is unknown, but may be may be due to a direct
effect on the pyronaridine mechanism of action. Cross
resistance with chloroquine in vitro appears to be in-
complete and inconsistent, whereas, in vivo pyronaridine
retains activity against chloroquine-resistant strains.
Thus, there may be important differences between
chloroquine and pyronaridine resistance and more than
one resistance mechanism may operate in order to over-
come the high potency of pyronaridine against P.
falciparum.
The activity of pyronaridine against chloroquine-
sensitive and -resistant field isolates from China and
Cambodia showed no evidence of cross resistance be-
tween pyronaridine and chloroquine [11]. Pyronaridine
was also reported to be significantly more active against
a chloroquine-resistant strain from Thailand compared
with a chloroquine-sensitive strain from Tanzania [32].
Wu et al. [43] described an increase in the number of
food vacuoles in trophozoites from a pyronaridine-
resistant P. berghei (RP) line, some of which were fusing.
There was also a marked reduction in the digestive food
vesicles containing malaria pigment granules for both
trophozoites and schizonts and typical haemozoin grains
were not formed in the pyronaridine-resistant parasites
[43]. These and other ultrastructural differences sug-
gested that resistance may be due to a direct effect on
the pyronaridine mechanism of action.
Li et al., found over-expression of a 54 kDa protein in
a pyronaridine-resistant strain of P. berghei (ANKA)
[44]. The protein was localized mainly in the cytoplasm
of erythrocytic stage trophozoites, schizonts and mero-
zoites and less commonly in the cytoplasm of infected
erythrocytes [44]. Interestingly, a 54 kDa protein is also
expressed in chloroquine-resistant P. berghei (ANKA)
suggesting a common effect, though whether this is
related to resistance development per se is unknown
[44].
Shi et al. described the relationship between pyronari-
dine resistance and the alteration of parasite polyamine
metabolism [45]. Infection with a P. berghei (PRB) strain
of high pyronaridine resistance significantly increased
the concentrations of putrescine and spermidine versus
a low pyronaridine resistant strain (PRA) by 1.8-fold and
1.7-fold and versus a pyronaridine-susceptible strain by
3.9-fold and 2.6-fold, respectively. Treatment of the
pyronaridine-susceptible strain with 5 mg/kg pyronari-
dine decreased spermidine by 31.6% and spermine by
47.3%. In contrast, there was no change in polyamine
levels in erythrocytes from mice infected with the highly
pyronaridine-resistant strain when treated with 10 mg/
kg pyronaridine [45].
In vitro resistance
One early study found that resistance in P. berghei
(ANKA) developed slowly to pyronaridine administered
at 4 mg/kg, with no detectable high resistance within 31
−45 passages [46]. However, higher doses were more ef-
fective at selecting for resistance [46]. More recently a
study using 4.7 mg/kg pyronaridine recorded the devel-
opment of resistance in P. berghei by the 15th passage
Croft et al. Malaria Journal 2012, 11:270 Page 4 of 28
http://www.malariajournal.com/content/11/1/270
with an increase in ED90 from 0.8 to 4.4 mg/kg, though
by the 35th passage a peak ED50 of around 13.8 mg/kg
was achieved and this did not increase with up to 50
passages [47].
The stability of pyronaridine resistance was also stud-
ied. Pyronaridine resistance established in P. berghei
after 50 passages was mostly maintained after transfer
through mice for five passages [47]. However, another
study reported greater instability of pyronaridine resist-
ance [48]. Here, pyronaridine-resistant P. berghei
achieved after 35 passages (resistance >299 fold) was
passed through mice given intragastric pyronaridine
600 mg/kg over three days. After 49 passages, relief of
drug pressure restored pyronaridine sensitivity after five
passages. After 115 passages, pyronaridine sensitivity
started to return after 21 drug-free passages. Pyronari-
dine resistance was stable only after 134 passages, with
no decrease in resistance after 31 drug-free passages and
with cross resistance to chloroquine [48].
In vivo resistance with combination therapy
Concomitant dosing of pyronaridine 4 mg/kg, sulpha-
doxine 5 mg/kg and pyrimethamine 1 mg/kg led to the
development of low level resistance to all three agents
by passage 31−34 [46]. However, in the same number of
passages, concurrent administration of pyronaridine
2 mg/kg with sulphadoxine 2 mg/kg or pyrimethamine
0.05 mg/kg prevented selection of pyronaridine resist-
ance and resistance to the triple combination [46]. This
was early evidence of the possibility for reducing resist-
ance selection with pyronaridine in combination
therapy.
Peters et al. were able to derive pyronaridine-resistant
P. berghei and Plasmodium yoelii strains by in vivo serial
passage, applying drug at 3 or 10 mg/kg [49]. However,
resistance development was slow, taking 140 days to
reach maximal levels and was more difficult to achieve
with the higher dose [49]. Further experiments using the
2% relapse technique with the combination of pyronari-
dine (1 mg/kg at each passage) and artesunate (300 mg/
kg at each passage) resulted in a marked delay in the de-
velopment of resistance in P. berghei versus pyronaridine
alone [50,51]. These results are encouraging as they indi-
cate that pyronaridine plus artesunate may retard the de-
velopment of resistance.
Resistance in clinical isolates
Data from China, where pyronaridine has been used
both as a monotherapy and in combination therapy for
around 40 years, suggests that resistance develops rela-
tively slowly, even in the presence of extensive chloro-
quine resistance.
An analysis of clinical cases from 1984−1985 (n = 36)
and 1995 (n = 39) in Yunnan Province, China showed a
decline in the in vitro susceptibility to pyronaridine
(ID50 13.0 nM in 1988 versus 40.0 nM in 1995) and an
increase in the rate of 28-day recrudescence from 15.2%
(5/33) to 37.5% (9/24) [52]. There was also an increase
in the time to clear fever in patients treated with pyro-
naridine over this period from 32.7 ± 16.0 h to 56.2 ±
27.4 h, though the time to parasite clearance was similar
(64.2 ± 22.9 h versus 55.3 ± 11.8 h, respectively) [52]. Al-
though this was a small study, other reports show that
in vitro resistance to pyronaridine in Yuxi Prefecture,
Yunnan Province, China, had emerged (38.1%), but at a
lower prevalence than for chloroquine (85.7%) and
piperaquine (66.7%) resistance [53]. Similarly, isolates
from the China−Laos border, south of Yunnan Province,
had a resistance prevalence of 34.5% to pyronaridine,
97.0% to chloroquine, and 96.4% to piperaquine [54]. A
more recent report showed that clinical isolates obtained
from Hainan and Yunnan Provinces during the malaria
transmission season showed a gradual decrease in pyro-
naridine sensitivity over time, with the mean drug con-
centration for complete in vitro inhibition of schizont
formation raised by two to four-fold. However, the clin-
ical therapeutic efficacy of pyronaridine remained satis-
factory [55].
Resistance in clinical isolates after combination
therapy
Combination therapy appears to decrease the potential
for pyronaridine resistance development. When pyronar-
idine−sulphadoxine−pyrimethamine (500/1,000/50 mg)
was administered as a single oral dose as the exclusive
treatment in the Diaoluo area in Hainan Province, sus-
ceptibility was maintained with a 100% cure rate over a
five-year period from 1986 [56].
Though data are limited, there was no evidence of the
development of resistance after unsuccessful treatment
with pyronaridine tetraphosphate−artesunate combin-
ation therapy: the initial pyronaridine mean IC50 was
23.39 ± 12.71 nM versus 22.96 ± 11.54 nM after recru-
descence in P. falciparum isolated from nine patients for
whom paired data were available [57].
Anti-malarial effect
Pyronaridine has been reported to have potent activity
against the erythrocytic stages of malaria infection in
mouse models [57,58]. Efficacy against P. berghei
ANKA for intragastric pyronaridine [45] and against P.
yoelii for subcutaneous pyronaridine [59] have been
demonstrated in mice. Indeed, pyronaridine exhibits
extended schizontocidal activity in mice [8], which was
more prolonged when compared with chloroquine [60].
The schizontocidal activity of pyronaridine has been
investigated in primate models of malaria infection. Effi-
cacy against P. inui has been demonstrated in Rhesus
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monkeys [57] and in P. cynomolgi intragastric pyronari-
dine was reported to be less effective than chloroquine
[61]. However, intravenous pyronaridine has been shown
to be more effective than the same dose of chloroquine
[62]. Efficacy has also been demonstrated for intramus-
cular pyronaridine in primates [57,62].
In vivo studies using pyronaridine with either artemisi-
nin, artesunate or DHA showed synergy and restored ef-
ficacy against strains resistant to the individual
components or impeded selection of resistance to these
compounds [26,41,50] indicating its potential in delaying
the selection and spread of resistance.
Initial in vitro data indicated strong gametocytocidal
activity of pyronaridine against two multi-drug resistant
P. falciparum isolates (KT1 and KT3) [63]. However,
these findings were not supported by in vivo studies
where no changes in gametocyte density or morphology
up to 24 h after administration were observed [59].
Murine models
Effect in erythrocytic stages
Pyronaridine has proved highly effective against the
erythrocytic stages of malaria infection in mouse models.
Early work in mice infected with P. berghei (Day 0) and
given pyronaridine on Day 3, found that the ED50 at Day
6 was 6.8 ± 1.4 mg/kg (n = 4) for oral administration and
4.97 ± 0.65 mg/kg (n = 7) for IM administration; corre-
sponding values for chloroquine were 45.6 ± 6.3 mg/kg
and 30.89 ± 5.8 mg/kg, respectively [3,64]. Thus, pyro-
naridine, after oral or IM administration was approxi-
mately 6.7-fold and 6.2-fold more active than
chloroquine, respectively [3,64]. An ED50 of 2.7 (95%CI
2.2−3.3) was reported for intragastric pyronaridine ver-
sus 16.7 (12.8−21.7) mg/kg for chloroquine, 9.1 (10−14)
mg/kg for sulphadoxine and 4.3 (2.6−7.1) mg/kg for
pyrimethamine in mice infected with P. berghei ANKA,
which is susceptible to these four drugs [46]. In fact,
combination therapy with pyronaridine (10 mg/kg) and
sulphadoxine−pyrimethamine (3 mg/kg) was no more
effective in clearing parasitaemia than pyronaridine
alone (P > 0.05) in mice infected with P. berghei (ANKA)
[65]. Efficacy against P. yoelii for subcutaneous pyronari-
dine 30 mg/kg has also been demonstrated in mice
where 5/5 treated mice had no parasites at Days 5, 6 and
12 versus 1/5, 0/5 and 0/5 for controls, respectively [66].
In addition, pyronaridine exhibits schizontocidal activ-
ity for a longer duration compared with chloroquine: at
1.47 x the ED50 (10 mg/kg) pyronaridine was suppressive
against P. berghei infection when given six days before
inoculation, whereas chloroquine at the same relative
ED50 (67 mg/kg) needed to be given two days before in-
oculation [5,67]. Follow-up experiments showed that
pyronaridine 10 mg/kg (3x ED50) given to mice up to
three days before inoculation with P. berghei (ANKA)
protected 10−50% of animals from infection, whereas a
3 mg/kg dose of sulphadoxine/pyrimethamine (2:1, 4x
ED50) had no protective effect [59]. Further evidence for
an extended schizontocidal effect of pyronaridine comes
from a study in mice infected with P. berghei N [8]. Pyr-
onaridine at concentrations of 25 μmol.kg-1 and above
was completely effective in clearing parasites from blood
by Day 2 (n = 6). There was some recrudescence of para-
sitaemia at Day 4 (< 20% of baseline), though this had
decreased to zero by Day 28 with 5/6 mice surviving. In
contrast, recrudescence in animals treated with amodia-
quine occurred from Day 4 and all mice were dead by
Day 14 [8].
Effect against tissue schizonts
Studies in China found that pyronaridine (2.5 mg/kg)
had no effect on the schizontocidal effect of primaquine
against P. yoelii tissue schizonts in mice (n = 10) [59]. A
later study confirmed that pyronaridine (10−100 nM)
did not inhibit the growth of P. yoelii sporozoites in
C57BL/6 mouse hepatocytes in vitro [66].
Effect against drug-resistant strains
In mice, oral pyronaridine was found to be equally ef-
fective against chloroquine-sensitive and chloroquine-
resistant P. berghei. The ED50 (n = 4/group) for three
doses was 2.01 ± 0.19, 2.04 ± 0.26 and 2.61 ± 0.44 mg/
kg for the sensitive versus 1.99 ± 0.27, 2.66 ± 0.36 and
2.88 ± 0.48 mg/kg for the resistant strain, giving a resist-
ance index (resistant/sensitive ED50) of 0.99−1.11 [64].
However, attenuation of oral pyronaridine efficacy
against a chloroquine-resistant strain has been reported
[68]. Pyronaridine (intragastric) 25 or 50 mg/kg over
four days cured 8/10 (recrudescence Day 24 and 31) and
10/10 mice infected with drug-sensitive P. berghei
(ANKA), respectively; no mice died. Pyronaridine was
more effective than amodiaquine (50 or 100 mg/kg/
4 days), mefloquine (50 or 100 mg/kg/4 days) and arte-
misinin (200 or 400 mg/kg/4 days) [68]. Against a
chloroquine-resistant P. berghei NS strain, 10/10 mice
were initially parasite free at both pyronaridine doses,
but recrudescence occurred from Day 12 in eight mice
in the 25 mg/kg group and from Day 8 in three mice in
the 50 mg/kg group; one mouse in each group died.
However, it was also noted that amodiaquine (200 or
400 mg/kg/4 days), mefloquine (200 or 400 mg/kg/
4 days) and artemisinin (800 mg/kg/4 days) were com-
pletely ineffective against this strain [68].
Pyronaridine (SC/4 days) efficacy in mice for seven P.
berghei lines with resistance to various anti-malarials
was similar to the chloroquine-susceptible P. berghei N
strain [49]. Against chloroquine-resistant P. berghei RC,
the ED50 was 0.5 mg/kg/day, similar to the ED50 against
P. berghei N (0.4 mg/kg/day), whilst the ED90 was
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10.0 mg/kg/day and 0.9 mg/kg/day, respectively [49].
Only against quinine-resistant P. berghei was the pyronari-
dine ED50 increased (to 38 mg/kg/day) [49]. Pyronaridine
efficacy was unimpaired against chloroquine-resistant and
mefloquine-resistant P. yoelii versus P. yoelii nigeriensis
(ED50 0.6, 0.9, 0.3 mg/kg/day, ED90 1.2, 1.4. 0.7 mg/kg/day,
respectively) but was decreased for a halofantrine-resistant
strain (ED50 8.0 mg/kg/day, ED90 >100 mg/kg/day) [49].
In mice infected with lethal multi-drug resistant P.
yoelii nigeriensis (resistant to chloroquine, mefloquine,
quinine, amodiaquine, mepacrine and halofantrine), par-
enteral pyronaridine (> 2.5 mg/kg/day for 3 or 4 days)
was highly effective against blood schizonts, protecting
animals completely (n = 54), whereas 14/14 control mice
died [69]. A similar experiment using the same
multidrug-resistant strain found that oral pyronaridine
10 mg/kg/day for seven days (n = 14) protected mice
against mortality for 28 days, though there was a transi-
ent parasitaemia at Day 24 [70]. However, a 15 mg/kg/
day dose (n = 19) for seven days was completely curative.
All control animals died by Day 10 (n = 10) [70].
Cross-resistance between pyronaridine-resistant strains
and other anti-malarials has also been investigated.
When the highly pyronaridine-resistant P. berghei PR
line was used, as expected, all mice treated with pyronar-
idine (400 mg/kg/4 days) had parasitaemia at Day 4 and
4/10 mice died; cross resistance was seen with meflo-
quine, amodiaquine and artemisinin [68]. Further experi-
ments in mice infected with the pyronaridine-resistant
P. berghei PR line indicated cross resistance with chloro-
quine, piperaquine, quinine and quinacrine [61]. How-
ever, pyrimethamine and sulphadoxine retained activity,
and in combination showed synergistic activity against
this strain. Artemisinin was also effective, but at a higher
dose than for the pyronaridine-susceptible strain [61].
Effect in combination therapy with artemisinins
The in vivo efficacy of pyronaridine has been studied in
combination with both artemisinin and artesunate
[11,42]. Importantly, there is some evidence to suggest
synergy between pyronaridine and artemisinin/artesu-
nate, restoring efficacy against strains resistant to the
drugs individually. This may have significant implica-
tions for delaying the selection and spread of resistance.
Pyronaridine (subcutaneous/4 days) ED50 in mice was
1.4 mg/kg/day against chloroquine-resistant P. yoelii NS,
48.5 mg/kg/day against an artemisinin-resistant strain
and 17.0 mg/kg/day against a pyronaridine-resistant
strain; corresponding values for artemisinin were 12.0,
47.5 and 15.2 mg/kg/day. Interestingly, though the effect
of pyronaridine−artemisinin-based combination therapy
was only additive against the NS strain, there was
marked synergism for both parasites that were resistant
to one or both anti-malarials [42].
These findings have recently been confirmed in a
study of pyronaridine−artesunate (3:1 ratio) in P. berghei
infection in mice [11]. Against P. berghei NY (drug sus-
ceptible), the ED50 for pyronaridine was 0.42 mg/kg,
artesunate was 5.1 mg/kg and the combination was
1.12 mg/kg and the ED90s were 0.8, 31.19 and 1.87 mg/
kg, respectively [11]. Against a pyronaridine-resistant
strain (NPN) the ED50/90 for pyronaridine was 0.57/
30.83 mg/kg, for artesunate was 0.24/204.17 mg/kg and
the combination 0.42/13.06 mg/kg. Against artesunate-
resistant P. berghei (SANA) the ED50/90s for pyronari-
dine, artesunate and combination respectively, were
0.89/2.29 mg/kg, 4.50/420.73 mg/kg and 1.46/2.10 mg/
kg. Based on ED90, pyronaridine was 38.5-fold less active
against the NPN strain versus NY, whereas the combin-
ation was only seven-fold less active. The combination
had almost the same activity against the SANA strain as
for the NY strain. Interestingly, the combination was
more active against both resistant strains than either
pyronaridine or artesunate alone [11].
In a curative model of Plasmodium chabaudi infection
in mice, pyronaridine 3 mg/kg or artesunate 4 mg/kg
were ineffective when given alone over three days [11].
In fact, pyronaridine 6 mg/kg was needed to cure 5/5
mice for 28 days. However, just 3 mg/kg pyronaridine
plus 1 mg/kg artesunate was effective in suppressing in-
fection in 4/5 mice for 28 days and in sub-inoculated
mice for a further 28 days without recrudescence [11]. A
6 + 2 mg/kg and 12 + 4 mg/kg pyronaridine plus artesu-
nate dose was effective in 5/5 mice throughout the ob-
servation period [11]. This study suggests that
pyronaridine plus artesunate in combination may allow
a lower dose of pyronaridine to be used than when
administered as monotherapy.
Primate models
Pyronaridine has also been tested for schizontocidal ac-
tivity in primate models of malaria infection. In Plasmo-
dium inui-infected rhesus monkeys (n = 3) given a single
oral dose of pyronaridine 28 mg/kg, asexual parasitaemia
was cleared in 64−144 hours, with recrudescence occur-
ring 11−33 days after dosing [64].
Pyronaridine (10 mg/kg) had no effect on the schizon-
tocidal effect of primaquine against Plasmodium cyno-
molgi sporozoites in rhesus monkeys (n = 3) [59].
Similarly, oral pyronaridine (24 mg/kg/day/6,/3, or/
1 days) had no tissue schizonticidal effect in rhesus
monkeys infected with P. cynomolgi, though a residual
blood schizonticidal action was observed [62].
Intragastric pyronaridine did not perform as well as
chloroquine in monkeys infected with P. cynomolgi [58].
Pyronaridine 6 mg/kg for three days cleared parasit-
aemia in 2/4 monkeys in a mean time of 77 ± 44 h,
though chloroquine cleared parasitaemia in 4/4 monkeys
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in 66 ± 12 h. A single dose of 30 mg/kg pyronaridine in
this model cleared parasitaemia (n = 2) in 54 ± 6 h, simi-
lar to the clearance time with chloroquine (n = 2, 60 ±
17 h). A 30 mg/kg dose but given over three days cleared
parasitaemia in 66 ± 12 h with pyronaridine (n = 4) and
52 ± 14 h with chloroquine (n = 4). However, all six
monkeys treated with pyronaridine 30 mg/kg had recru-
descence at 12−22 days, followed by four to five recru-
descences on repeated therapy. There was one
recrudescence in the 30 mg/kg over three days chloro-
quine group with no recrudescence after a second treat-
ment course [58].
Intramuscular pyronaridine 9 mg/kg given over two
days to P. cynomolgi-infected monkeys (n = 4) cleared
parasitaemia in 48−120 h with recrudescence at 10−18
days [64]. In the same model (n = 5), higher doses of pyr-
onaridine (IM 20 mg/kg in two divided doses six hours
apart) cleared parasitaemia after three to four days, and
cured all monkeys with no recrudescence over three
months of follow up [71,72].
Intravenous pyronaridine 6 mg/kg over one hour
(n = 3) cleared P. cynomolgi parasitaemia in 73−97 h with
recrudescence at seven to eight days; the same dose of
chloroquine (n = 3) cleared parasitaemia in between 93
−120 h with recrudescence within one to two days [64].
Intravenous pyronaridine 2−5 mg/kg given to monkeys
infected with Plasmodium knowlesi (n = 7) cleared para-
sitaemia within 48−72 h with recrudescence at four to
11 days [64].
Gametocytocidal activity
Initial in vitro data indicated strong gametocytocidal ac-
tivity of pyronaridine against two multi-drug resistant P.
falciparum isolates (KT1 and KT3) cultured for 14 days
after 48 h of drug exposure [63]. Pyronaridine had an
IC50 of 6 nM for KT1 and 20 nM for KT3 and was more
active than four other agents, including primaquine
(IC50 800 nM and 2100 nM, respectively).
However, these findings are not supported by in vivo
tests. After 0.1 mg/kg pyronaridine was given to P. ber-
ghei ANKA-infected mice, there were no changes in
gametocyte density or morphology two or 24 h after ad-
ministration [59]. When Anopheles stephensi were fed
on mice infected with P. berghei (ANKA) after treatment
with pyronaridine (0.5 mg/kg) plus sulphadoxine−pyri-
methamine (0.3 mg/kg, 2:1), sulphadoxine−pyrimeth-
amine (0.3 mg/kg) alone, or sulphadoxine (0.2 mg/kg)
and pyrimethamine (0.1 mg/kg) separately, there was no
impact of pyronaridine on the oocyte gut-positive or
gland-positive rates in the dissected mosquitoes [65].
Further, similar experiments confirmed no additional ef-
fect of pyronaridine on gametocytes when added to sul-
phadoxine−pyrimethamine [59].
In terms of gametocydal activity in man, clinical evi-
dence from adults and children shows no relevant effect
of pyronaridine monotherapy on gametocyte carriage of
P. falciparum [73]. However, chloroquine was associated
with a higher relative risk (11.5) of post-treatment game-
tocytaemia versus pyronaridine (1.25) in patients who
had chloroquine-resistant infection [73]. This suggests a
relative benefit of pyronaridine versus chloroquine for
gametocyte carriage in areas where chloroquine resist-
ance may be a problem.
In patients treated for P. falciparum malaria with pyr-
onaridine in combination with sulphadoxine−pyrimeth-
amine (800 + 1000 + 50 mg over two days or
500 + 1500 + 75 mg or 500 + 1000 + 50 mg/1 day) game-
tocytemia remained high: 47/57 (82.5%) at Day 14 and
41/57 (71.9%) Day on 28, though gametocyte density
was reduced from 254.2 parasites per μL on Day 14 to
27.5 parasites per μL on Day 28 [59]. Examination of
batches of Anopheles dirus that were fed on six gameto-
cytaemic patients four, eight, 10, 14, 19 and 27 days after
treatment showed that although many oocysts were
retarded, sporogony of P. falciparum was not completely
suppressed [59].
There is one report including 12 patients with initial
Plasmodium malariae and P. ovale gametocytes who
had complete gametocyte suppression at Day 3 after pyr-
onaridine therapy [74]. However, overall, pyronaridine
should be considered to have no clinically relevant effect
on P. falciparum gametocyte carriage.
Toxicological profile
Single oral dose toxicology studies in the rat demon-
strated that the inherent acute toxicity of pyronaridine
was low with findings of decreased body weight gain,
diarrhoea and soft stools at ≥1,000 mg/kg and chroma-
turia at 2,000 mg/kg.
The effect of 3 days of oral dosing with pyronaridine
was examined in the dog and primate. In dogs doses up
to 240 mg/kg pyronaridine (total dose) resulted in
vomiting, but no other serious adverse effects. Hyper-
aemia of the intestinal mucosa and focal hyperaemia of
the gastric mucosa was noted in 1 animal [64,72]. In
monkeys, pyronaridine (240 mg/kg total dose) elevated
serum glutamate pyruvate transaminase (SGPT) in one
animal returning to normal after one week, there were
no other adverse effects [64,72].
Intramuscular pyronaridine was examined in mice
(LD50 was ~250 mg/kg), rabbits (20, 40 and 80 mg/kg;
one death occurred at 80 mg/kg and ECG changes at all
doses with the number of changes increasing with dose),
and dogs (20, 40 and 60 mg/kg; one death occurred at
60 mg/kg, convulsions in another animal and elevated
SGPT in a third) [64,72].
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In recent sub-acute toxicity studies in the rat and dog the
NOAEL following 28 days of treatment was 23 mg/kg/day
and 5 mg/kg/day, respectively. Findings included yellow
colouration of skin, eyes, urine and tissues/organs, accumu-
lation of basophilic material usually accompanied by
chronic inflammation predominantly in liver, bone marrow,
spleen, lung and kidney. Marked hepatocellular hyper-
trophy and hyperplasia in spleen and bone marrow were
also observed in the rat and decreased red blood cell para-
meters and increased liver enzymes were observed in the
dog. Partial or total recovery was evident in some tissues
after a two-week recovery period but in other tissues an
increase in severity was noted [75].
Earlier repeat dose toxicology studies had been conducted
in rats and dogs. In rats were given 40 or 200 mg/kg/day
oral pyronaridine for 14 days. All animals had retarded
growth and three died within the 14-day study period in
the 200 mg/kg/day group. [64,72]. In dogs, oral pyronari-
dine 12 or 24 mg/kg/day for 30 days was well tolerated with
no changes in laboratory parameters or ECG. [5,64,72]. In
rabbits, IV pyronaridine (20 mg/kg on Day 1 and 10 mg/kg
for Days 2−7) showed good tolerability [64,72].
Pyronaridine in combination with artesunate 28-day
oral dosing in rats, and cyclic dosing studies in the rat
and dog (three consecutive days dosing per week for two
or four weeks) showed that the findings were in line
with those observed for pyronaridine alone. Results from
the 4-cycle studies showed extensive tissue accumulation
of pyronaridine and, although the 6 (rat) or 8 (dog) week
recovery study was sufficiently long for some of the
histopathological changes to have resolved, other
changes, such as inflammatory and degenerative changes
in liver and the presence of basophilic granules and
macrophage accumulation in various tissues, persisted
[76].
Pyronaridine possesses some potential for in vitro gen-
otoxicity as shown in the bacterial mutagenicity test, due
to its property as an intercalator. Its “genotoxic” effects
in mammalian cells however, i.e. the induction of
chromosomal aberrations and, in particular, polyploidy,
are considered related to its property as a catalytic in-
hibitor of topoisomerase II [76]. A number of studies
were performed to examine the in vivo genetic toxicity
profile of pyronaridine including micronucleus studies, a
liver UDS study and a COMET assay. These studies pro-
vided uniformly negative results at the highest tolerated
doses of pyronaridine [76].
In reproductive toxicity studies pyronaridine had no
effects on rat male fertility at doses up to 180 mg/kg/day.
Pyronaridine tetraphosphate when dosed daily during the
sensitive periods of embryonic organogenesis to pregnant
rats and rabbits) at levels up to 420 and 120 mg/kg/day, re-
spectively resulted in maternal toxicity at the highest levels
but no evidence of teratogenicity [76].
Othe potential toxicities of pyronaridine were exam-
ined. There was no evidence of cytotoxicity [8,77] or
phototoxicity [78]. A mild local injection site irritation
was noted in rabbits dosed IM [5]. Transient increases
in serum alanine aminotransferase (ALT) were reported
in 1 monkey and 1 dog, but no consistent increases were
observed in animal studies.
A series of safety pharmacology studies were under-
taken with pyronaridine. In brief these studies demon-
strated that pyronaridine decreased urine volume with a
concomitant increase in density and electrolyte concen-
tration at 500 mg/kg, decreased gastric acidity and vol-
ume of secretion at doses of 100 mg/kg and above in the
rat. Decreases in body temperature were noted in the
mouse (300 and 1000 mg/kg, but not the dog (up to
60 mg/kg). Pyronaridine produced a significant analgesia
in the acetic acid writhing test (≥ 300 mg/kg). No effects
were noted in the following studies: Irwin, spontaneous
motility, motor co-ordination, hexobarbital sleep time,
hot-plate test, convulsion induction, isolated ileum, GI
transit time, respiratory rate and tidal volume, and car-
diovascular parameters in the telemetered dog. In vitro
cardiovascular studies (hERG test and Purkinje fibre
assay) showed that pyronaridine inhibited the hERG
channel with an IC50 of 0.65 μM. In the Purkinje fibre
study at a concentration of 3,500 ng/mL small decreases
in action potential duration and the rate of rise of the ac-
tion potential upstroke were observed, but not at lower
concentrations, indicating that pyronaridine blocks so-
dium, calcium and the hERG potassium channel.
The toxicological profile of oral pyronaridine was ini-
tially investigated at the Institute of Parasitic Diseases in
the Chinese Academy of Medical Sciences, and pub-
lished, in Chinese, in their annual reports [60,64,79].
These data have also been reviewed in English by Shao,
Fu and Xiao, Chen and Zheng, and Chang et al.
[3,5,72,80]. The main findings reported in these papers
have been collated and summarized below, with refer-
ence to any additional data. Overall, the acute and sub-
acute toxicity of pyronaridine was generally less than
that of chloroquine in all animal species tested (Add-
itional files 3 and 4) [5,63,66,71,79,80]. Cardiovascular
toxicity was also less than that of chloroquine
[3,5,71,79]. There were no unexpected findings that
would be a particular cause for concern at therapeutic
levels in human subjects. However, evidence of embryo-
toxicity in rodents suggests that pyronaridine should be
used with caution during pregnancy [76,81].
Acute toxicity
The main findings from acute toxicity studies with
pyronaridine are summarized in Additional file 3
[5,63,66,71,79,80].
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Oral administration
LD50s for oral pyronaridine have been reported in a
number of studies [63,66,71,80] and these are referred to
in Additional file 3. Dogs given oral pyronaridine
120 mg/kg (n = 2) or 240 mg/kg (n = 2) (25% of total
dose on Day 1 then once daily for the next two days)
experienced vomiting, but no other serious adverse
effects. Autopsy was carried out in two dogs, one of
which had hyperaemia of the intestinal mucosa and focal
hyperaemia of the gastric mucosa [63,71].
In monkeys (n = 4), pyronaridine 240 mg/kg (60 mg/kg
twice on Day 1 then once daily for two days) elevated
serum glutamate pyruvate transaminase (SGPT) in one
animal from 20 to 107 IU/L, returning to normal after
one week, though there were no other adverse effects
[63,71].
In a recent study there were no mortalities up to and
including a dose of 2,000 mg/kg in the rat. Clinical find-
ings of diarrhoea and soft stools were found at
≥1,000 mg/kg and one incidence of chromaturia was
reported at 2,000 mg/kg in males. Suppression of body
weight gain was observed from Day 1 to Day 3 of the
study in 1,000 and 2,000 mg/kg groups [82].
Non-oral administration
IM pyronaridine LD50 in mice was reported as 250.6 ±
33.1 mg/kg, 2.8-fold higher than that of chloroquine
(89.7 ± 34.0 mg/kg) [63,71].
In rabbits, a single IM dose of pyronaridine 80 mg/kg
(n = 5), 40 mg/kg (n = 4) or 20 mg/kg (n = 5) resulted in
one death after 40 min (80 mg/kg, minimal lethal dose
[MLD]). Electrocardiogram (ECG) changes, including
premature ventricular beats and ventricular fibrillation
were seen at the 80 mg/kg dose. Reversible bradycardia
was observed at the 40 mg/kg dose, with prolonged
QRS, P−R and Q−T, and arrhythmia. Prolonged QRS
was seen at the 20 mg/kg dose, resolving within one
hour after dosing as well as arrhythmia. Otherwise, pyro-
naridine was well tolerated. In comparison, mortality
was 3/3 with chloroquine 80 mg/kg, 1/5 at 40 mg/kg
and 1/4 at 20 mg/kg within 24 h after administration; re-
versible bradycardia was observed with chloroquine at
the 20 mg/kg dose [63,71].
In dogs, a single IM dose of pyronaridine 20 mg/kg
(n = 5) or 40 mg/kg (n = 5) was well tolerated. Pyronari-
dine MLD in dogs was 60 mg/kg dose, resulting in 1/3
deaths at 23 min after administration. A clonic convul-
sion at 20 min and vomiting after 24 min were observed
in a second dog, with recovery by the next day, and a
third dog had raised SGPT (22.5 to 85 IU/L), resolving
within a week. No further adverse effects were observed
in surviving dogs over one month of follow up. Com-
parative data for IM chloroquine showed mortality rates
of 2/2 for 20 mg/kg and 1/3 for 10 mg/kg within
24 min. Two surviving dogs receiving 10 mg/kg chloro-
quine and three given 5 mg/kg showed tremor and white
foam spitting, but all recovered within 24 h. ECGs
showed delayed conduction with chloroquine, resolving
within two hours [63,71].
Intravenous 30 mg/kg pyronaridine given over one
hour in rabbits (n = 10) was sub-lethal, though ECG
changes were observed, notably fused T and P waves and
prolonged P−R and QRS. In this experiment, chloro-
quine 5 mg/kg caused one rabbit to die from severe
hypotension and ECGs showed occasional prolongation
of P−R, broadened QRS and bradycardia [3].
Sub-acute toxicity
The main findings for sub-acute toxicity studies with
pyronaridine are summarized in Additional file 4
[5,63,71]. Sub-acute toxicity studies were conducted in
rats given either 40 mg/kg/day (n = 15) or 200 mg/kg/
day (n = 15) oral pyronaridine for 14 days. In the 40 mg/
kg/day group, one rat died on Day 13, though the growth
and development of the survivors was unaffected. However,
in the 200 mg/kg/day group, all animals had retarded
growth and three died within the 14-day study period. In
comparison, rats given 100 mg/kg/day chloroquine experi-
enced more severe growth retardation than with pyronari-
dine and three animals died [63,71].
In dogs, oral pyronaridine 12 mg/kg/day (n = 2) or
24 mg/kg/day (n = 2) for 30 days was well tolerated with
no changes in laboratory parameters or ECG. The same
daily dose of oral chloroquine elicited multiple symp-
toms including salivating, tremor, vomiting and white
foam spitting and all the animals died; death on Day 8
and Day 30 for the 12 mg/kg/day dose (n = 2) and on
Day 5 and Day 14 for the 24 mg/kg/day dose (n = 2)
[5,63,71].
A sub-acute toxicity study in rabbits with IV pyronari-
dine 20 mg/kg (n = 5) on Day 1 and 10 mg/kg for Days 2
−7 showed good tolerability, though chloroquine (n = 5)
at the same dose led to one death after 20 min during
the fifth administration [63,71].
In recent sub-acute toxicity studies in the rat the
NOAEL following 28 days of treatment was 23 mg/kg/
day. Findings included yellow colouration of skin, eyes,
urine and tissues/organs, accumulation of basophilic
material usually accompanied by chronic inflammation
predominantly in liver, bone marrow, spleen, lung and
kidney. Marked hepatocellular hypertrophy and hyper-
plasia in spleen and bone marrow were also observed.
Partial or total recovery was evident in some tissues after
a two-week recovery period but in other tissues an in-
crease in severity was noted [82].
In the dog the NOAEL following 28 days treatment
was 5 mg/kg/day [82]. Findings included loss of appetite,
vomiting, body weight loss, decreased red blood cell
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parameters, increased liver enzymes, increase in liver,
lung, spleen, brain and kidney weight, yellow discolour-
ation of many tissues and organs, accumulation of baso-
philic material associated with chronic inflammation and
hyperplasia of a number of tissues.
Acute and sub-acute toxicity in combination
therapy
The LD50 in mice or rats was not affected when oral
pyronaridine was combined with sulphadoxine−pyri-
methamine (100/5 mg/kg) [66]. However, when pyronar-
idine plus sulphadoxine−pyrimethamine at 50%, 25% or
12.5% of the LD50 were tested there was an additive
toxic effect [66]. In mice, oral pyronaridine 600 mg/kg
had a slight antagonistic effect on the toxicity of prima-
quine, marginally increasing LD50 by about 34%; lower
doses had little impact on primaquine toxicity [80]. Pyr-
onaridine also had a protective effect on murine seven-
day mortality for primaquine 50 mg/kg given one hour
after pyronaridine dosing: 12/30 mice died with prima-
quine alone versus 6/30 that had received pyronaridine
507 mg/kg (0.38 LD50) (P < 0.05) [80]. A similar experi-
ment in rats given IM pyronaridine plus oral primaquine
(51 mg/kg) one hour later showed no effect of the com-
bination on seven-day mortality versus primaquine alone
[80]. The LD50 in rats was not affected when oral pyro-
naridine was combined with artesunate (pyronaridine
tetraphosphate: artesunate (3:1)), with similar findings to
those for pyronaridine alone. In addition a decrease in
locomotor activity was observed.
The sub-acute toxicity of pyronaridine combined with
artesunate was studied in a 28-day study in rats, and
cyclic dosing studies in the rat and dog (three consecu-
tive days dosing per week for two or four weeks). In
these studies the findings were in line with those
observed for pyronaridine alone. In addition, in the rat
the following changes were observed: increased haem-
atopoiesis in the spleen, thymic atrophy, hepatocyte
hypertrophy which was considered to be an adaptive
change due to enzyme induction in the liver, reactive
hyperplasia of the lymph nodes, follicular epithelial
hypertrophy of the thyroid glands and perivascular baso-
philic vacuoles with associated inflammation. A number
of these changes recovered during a six-week recovery
period, however, the changes in the liver, kidney and
spleen as well as the thymic atrophy persisted [82]. As
for the rat, in the dog the findings were in line with
those observed for pyronaridine alone [82]. In addition,
increased haematopoiesis in the spleen and perivasculitis
in the brain were observed. After an eight-week recovery
period most changes had either resolved or were greatly
reduced, however, the changes in the liver, gall bladder
and kidney, along with adaptive changes in the spleen
and bone marrow persisted.
Cardiovascular toxicity, intravenous challenge
In anaesthetized rabbits (n = 10), 4 mg of pyronaridine
(2 ml in 2% solution) was injected every two minutes
through the carotid vein. A 40 mmHg blood pressure
drop was obtained with a mean pyronaridine dose of
39.8 ± 9.6 mg/kg versus 11.4 ± 3.1 mg/kg for chloro-
quine (P < 0.01) [63,71]. ECG changes observed with pyr-
onaridine included fused T and P, prolongation of the
QSR, P−R and Q−T intervals and broadened S, followed
by A−V block, sinus bradycardia, premature ventricular
contraction leading to auto-ventricular rhythm and
death. The mean lethal dose in this study was 64.6 ±
10.1 mg/kg for pyronaridine versus 20.7 ± 3.8 mg/kg for
chloroquine (P < 0.01) [63,71].
A comparable experiment conducted in dogs (n = 5)
given 10 mg pyronaridine (5 ml every two minutes) indi-
cated hypotension at a dose of 97.8 ± 18.7 mg/kg versus
28.8 ± 4.4 mg/kg for chloroquine (P < 0.01). ECG
changes with pyronaridine in dogs were similar to those
observed in rabbits. The lethal pyronaridine dose in dogs
was 116.0 ± 22.3 mg/kg versus 47.4 ± 6.7 mg/kg for
chloroquine [63,71]. A cross-over study in anaesthetized
cats (n = 3) compared the effect on blood pressure of
pyronaridine 2 mg/kg and 4 mg/kg with that of chloro-
quine at the same dose. The decrease in blood pressure
with pyronaridine 2 mg/kg and 4 mg/kg was 6 and
20 mmHg at Day 1 and 20 and 40 mmHg on Day 2, re-
spectively. Corresponding results for chloroquine 2 mg/
kg and 4 mg/kg were 20 and 35 mmHg and 35 and
68 mmHg, respectively. Thus, chloroquine was between
1.7- and 3-fold more toxic than pyronaridine [5].
Mutagenicity/embryotoxicity
Pyronaridine mutagenicity was studied in the Salmonella
microsome system [83]. Five strains of histidine-
requiring Salmonella typhimurium (TA100, TA98,
TA1535, TA1537 and TA1538) with and without S-9
were used. Positive controls included hycanthone and
furapromide. Pyronaridine did not induce mutations in
four strains, but there was evidence of a mutagenic ef-
fect without S-9 for strain TA1537 that was dose-
dependent between 100−1,000 μg/plate [83]. There was
no structural damage to chromosomes or the spindle ap-
paratus with pyronaridine at the LD50 in the mouse
micronucleus test [84]. There was no effect of pyronari-
dine at 0.78 μg/ml on chromosomal aberration in Chin-
ese hamster fibroblast cells, though aberration rates
were 5−9.9% at the highest dose tested (2.34 μg/ml, 50%
of growth inhibiting dose) [5,85]. Mice were treated with
60, 685, 1370 mg/kg pyronaridine and bone marrow
smears were carried out 24 h after treatment. No muta-
genic activity was found [85].
A comprehensive battery of in vitro and in vivo genetic
toxicity studies has been conducted. In the Ames test,
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no evidence of bacterial mutagenicity was observed, and
a COMET assay showed no evidence for primary DNA
damage. An increased frequency of chromosomal aber-
rations in Chinese hamster lung and evidence of genetic
toxicity was observed in the mouse lymphoma assay
(±S9) [85]. In vivo, a series of mouse micronucleus
assays with pyronaridine were undertaken. Two assays
were reported as negative and two reported as positive.
It is noteworthy that both of the ‘positive’ studies with
pyronaridine utilized a bone marrow staining procedure
(May Grunwald/Giemsa stain) that would be unable to
discriminate between’true DNA-containing micronuclei’,
and potential artefact arising from non-DNA containing
granules, such as the RNA-containing granules (‘Q-bod-
ies’) such as has reported in mouse bone marrow after
treatment with quinacrine.
Maier and Schmid reported that quinacrine hydrochlor-
ide induced, not micronuclei, but irregularly shaped granu-
lar and fibrillar bodies that were negative in the Feulgen
reaction [86]. It has also been shown that the use of more
specific stains such as acridine orange allow the discrimin-
ation of such bodies from true micronuclei [87]. Such fib-
rillar bodies, although induced by the treatment with
quinacrine and thus observed in a dose-dependent fre-
quency, are not due to chromosome breakage, and hence
not indicative of any in vivo genotoxicity for quinacrine. It
is noteworthy that pyronaridine possesses a close structural
resemblance to quinacrine. In order to clarify the situation,
an additional mouse bone marrow micronucleus test was
performed using the same strain of mouse as in the
reported ‘positive’ studies (male ICR mice), and in which
the smears were prepared, and stained with a DNA specific
stain (acridine orange) prior to micronucleus analysis [87].
The results indicated that there was no increase in micro-
nucleus frequency in the bone marrow of male mice dosed
with pyronaridine (750 mg/kg). It was concluded that the
apparent increases in micronucleus frequency reported in
the earlier studies on pyronaridine were due to the presence
of non-DNA containing artefacts on the slides, which had
been incorrectly identified as ‘true micronuclei’ as a conse-
quence of the use of a staining procedure that was not spe-
cific for DNA. Furthermore, an in vivo COMET assay
examining the effects of pyronaridine in the liver and an
unscheduled DNA synthesis assay provided no evidence for
a direct DNA damaging effect of pyronaridine and were
both negative.
In order to explain the discrepancy between the
in vitro and in vivo data the effects of pyronaridine on
topoisomerase II were examined in an inhibition assay
and a TARDIS (Trapped in Agarose DNA Immunostain-
ing) study [82]. It was shown that pyronaridine is a weak
topoisomerase II catalytic inhibitor with an IC50 of ap-
proximately 32.7 μM. At in vitro concentrations below
5–8 μM topoisomerase II activity was not affected. In
these studies there was no evidence that pyronaridine
was acting as a topoisomerase II poison.
In addition, the effect of pyronaridine on topoisomer-
ase II in mammalian cells was investigated using the
TARDIS assay. The results indicated that pyronaridine
was increasing the number of topoisomerase II mole-
cules complexed with cellular DNA, and that it thus
may be acting as a topoisomerase II poison. This could
be due to a direct interaction between pyronaridine and
topoisomerase II or due to an indirect mechanism such
as inhibition of removal/repair of the topoisomerase II
complexes on DNA. Clearly this conclusion contrasts
with that discussed for the previous study in which puri-
fied human topoisomerase II enzyme was used and the
absence of linear DNA indicated that pyronaridine was
acting as a catalytic inhibitor rather than as a topoisom-
erase II poison. However ‘stable cleavage complex’ for-
mation was seen over a higher test concentration range
than that used in the “catalytic inhibition” study [82].
The current data on pyronaridine indicates that the
compound may act as both a catalytic inhibitor and a
topoisomerase II poison dependent upon exposure con-
centration. It is clear that either mechanism of action
would explain the in vitro clastogenicity of pyronaridine
towards Chinese Hamster CHL cells and the induction
of small colony tk mutants in mouse lymphoma L5178Y
cells. In male mouse dominant lethal tests there was no
evidence of a mutagenic effect or any effect on gameto-
genesis or fertilization with pyronaridine [88]. In this
study, groups of 10 male mice were treated with oral
pyronaridine 1,029, 514.5 or 258 mg/kg over three days
before mating; one male in the highest dose group died.
Mated females were sacrificed on Day 15 after mating.
Versus controls there were no apparent differences for
the pyronaridine-treated group in the percentage of
females with implants, average implants, average live
foetuses and foetus death rate [88].
Embryotoxicity, but no teratogenicity has been
observed in rats with pyronaridine [80,81]. In a study by
Ni et al., oral pyronaridine at 84 mg/kg (n = 20),
165 mg/kg (n = 19) or 330 mg/kg (n = 19) for three days
or 1,100 mg/kg (n = 19) for one day beginning from D7
of gestation increased the foetal resorption rate in rats in
a dose-dependent manner [76]. Pyronaridine also
delayed ossification of the occipital bone and sternum of
foetuses, though no visceral or skeletal abnormalities
were observed [76]. Shao et al. administered pyronari-
dine 10 mg/kg (n = 14) or 20 mg/kg (n = 10) to male rats
for 60 days before mating and female rats from 14 days
before and throughout gestation [81]. The rate of
resorbed foetuses was 13.3% (4/30) for 10 mg/kg and
29.5% (13/44) for 20 mg/kg pyronaridine, the latter
being significantly higher versus controls (7.5% [11/146],
P < 0.05). Foetal mortality was also increased for the
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20 mg/kg dose versus controls: 29.5% (13/44) versus
14.4% (21/146), P < 0.05. The number of live litters was
2.3 ± 2.7 in the 20 mg/kg pyronaridine group, signifi-
cantly lower than for the control group (5.7 ± 2.8,
P < 0.01). No evidence of embryotoxicity was observed in
the F1 generation. No external or skeletal abnormalities
were observed in the F1 and F2 generation rats [81].
In a recent series of studies pyronaridine did not ad-
versely affect male reproductive function. The NOAEL
was considered to be >180 mg/kg/day for reproductive
performance and early embryonic development for par-
ental animals. In rats, the NOAEL was between 6 and
47 mg/kg/day for dams. For embryo-foetal development,
the NOAEL was 140 mg/kg/day in rats and 40 mg/kg/
day in rabbits. Pyronaridine at 420 mg/kg/day resulted
in a decrease in foetal weight in rats. At 120 mg/kg/day
in rabbits, mean foetal weight reduction and a reduction
in the number of ossification centres of the first and sec-
ond phalanges in both hind limbs was observed. These
effects are considered to be a consequence of the mater-
nal toxicity observed at these doses. The NOAEL for
pyronaridine are considered to be 30 mg/kg for F1 off-
spring and >150 mg/kg for F2 foetuses [82].
Other toxicity
Cytotoxicity (neutrophils)
At one point amodiaquine was withdrawn from clinical
use after reports of neutrophil toxicity resulting in fatal
agranulocytosis [89]. As a consequence, it was consid-
ered important to re-evaluate the possibility of similar
adverse events occurring with both new anti-malarials
and those in current use. Pyronaridine is accumulated in
lysosomes, but no more so than with other anti-
malarials [89]. Moreover, there was no evidence of gluta-
thione depletion with pyronaridine, no significant tox-
icity to polymorphonuclear leukocytes or inhibition of
their function [89]. Oxidation of pyronaridine to a qui-
noneimine metabolite has been shown to deplete neu-
trophil glutathione in vitro [77]. However, in vivo studies
in rats failed to find any quinoneimine metabolites in
bile samples after pyronaridine dosing [8,90]. The clin-
ical relevance of these findings is unknown, and to date
there is no evidence of significant neutrophil toxicity
associated with pyronaridine use in humans.
Phototoxicity
No photoxic reactions were noted in mice exposed to
ultraviolet radiation for 24 h after IG administration of
pyronaridine 600 mg/kg (n = 20) or 800 mg/kg (n = 18).
Slight phototoxicity was seen with chloroquine 300 mg/
kg (n = 9) and 600 mg/kg (n = 10) in this study (swelling
and auricular erythema)[78]. In another study, no photo-
toxicity was seen in mice given IG pyronaridine 300 mg/
kg (n = 10) or chloroquine 100 mg/kg (n = 10) following
irradiation with black light for 24 h [91].
Injection site reaction
In rabbits, IM pyronaridine 40 mg/kg in 4% solution
caused mild local injection-site irritation that resolved
within two weeks [5].
Hepatotoxicity
Isolated and transient elevation of serum alanine amino-
transferase (ALT) was reported after acute dosing of pyr-
onaridine in one monkey (from 20 to 107 IU/L,
returning to normal after one week) with no concomi-
tant adverse effects. A transient rise in ALT (22.5 to
85 IU/L), which resolved within a week, was reported in
a dog following a 60 mg/kg single dose [63,71]. Transi-
ent increases in concentrations of hepatic enzymes have
been reported during the clinical programme of Pyramax
(pyronaridine-artesunate). In a few subjects, aspartate
aminotransferase (AST) and (ALT) concentrations of
three or more times the upper limit of normal were
reported, with a concomitant increase in total bilirubin
concentrations that were two or more times the upper
limit of normal, although there was no increase in alka-
line phosphatase concentrations.
Safety pharmacology
In a battery of safety pharmacology studies, the cardiovas-
cular, neurobehavioural, motor coordination and respiratory
effects of pyronaridine tetraphosphate were examined. Add-
itional studies were undertaken examining the effects on
analgesia and the GI and renal systems.
Pyronaridine inhibited hERG [human ether-à-go-go
related gene] tail current with an IC50 of 0.65 - 0.82 μM.
In the rat Langendorff significant decreases in LVP,
LVDP, HR, DP and CFR were observed at 10 μM pyro-
naridine. In a dog Purkinje fibre study, no effect was
noted on action potential duration at 350 ng/mL, and a
shortening of action potential duration observed at
3,500 ng/mL. In vivo, no effects were observed in the
dog telemetry study [5,63,71].
No effects were observed on the central nervous sys-
tem or on pain threshold at doses up to 1,000 mg/kg. A
significant analgesia was noted in the acetic acid writh-
ing test at doses of ≥300 mg/kg. No effects were noted
using the hot-plate method. Decreases in body
temperature were noted in the mouse (≥300 mg/kg), but
not in the dog (doses up to 60 mg/kg). A transient in-
crease in respiratory rate was observed at a dose of
500 mg/kg 2 h post-dose. No effect was noted on gut
motility, however small, but significant decreases, in gas-
tric acidity and volume of secretion were observed at
doses of 100 mg/kg and above in the rat. Significant
decreases in urine volume accompanied by increases in
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density and electrolyte (sodium) concentration were
observed with 500 mg/kg pyronaridine [76].
Pharmacokinetic profile
The pharmacokinetics of pyronaridine have been exam-
ined in the rat, rabbit, dog and rhesus monkey. In the
rat and dog following intravenous administration of pyr-
onaridine, the blood concentrations of pyronaridine
declined in a multi-exponential manner with an appar-
ent terminal half-life of 2 to 4 days. Intramuscular pyro-
naridine in the rabbit and rhesus monkey reached Tmax
within 0.75-1.5 h post-dose with an apparent half-life of
2 to 3 days [92,93].
The metabolism, distribution and elimination of pyro-
naridine in in vitro and in vivo models were examined.
In brief in vitro metabolism showed evidence of 8–12
metabolites. Subsequent profiling showed that all human
in citro metabolites were present in rat and dog systems.
Following oral administration of pyronaridine no signifi-
cant metabolism was observed with the major dose
related compenent found to be unchanged pyronaridine,
although in the rat after IP administration metabolites
were observed in urine and faeces. Incubations with re-
combinant human CYP450 isoforms indicated that pyro-
naridine could be metabolised by CYP1A2, CYP2D6 and
CYP3A4 [76].
Pyronaridine preferentially associates with blood cells
and is highly plasma protein bound. In mice, rats and
rabbits the highest concentrations of radioactivity were
typically located in the liver, spleen, adrenal gland, kid-
ney and thyroid. In the rat the half life of elimination
was 137–231 h [76].
Examination of the elimination of pyronaridine in the
rat (60 mg/kg dosed) found that around 93% wsas
excreted over 14 days, with the majority in the faeces. In
the dog (dose of 9 mg/kg) an overall recovery of 44%
was noted over the same duration. The shortfall in re-
covery was investigated and a significant proportion of
the dose remained associated with the liver [76]. At
10 mg/kg pyronaridine in the rat the majority of the
dose was eliminated in the urine [94].
Investigations into the pharmacokinetic characteristics
of pyronaridine were held back by the need to develop a
sensitive, simple and reliable assay. Sensitive HPLC [high
performance liquid chromatography] methods were
developed using the anti-malarials amodiaquine or quin-
ine as internal standards [4,95]. Most recently, Naik
et al. developed liquid chromatography-mass spectrom-
etry (LC-MS) assays for pyronaridine in both urine and
blood [92,96]. Both of these techniques used amodia-
quine as an internal standard, were reproducible and ac-
curate and had a lower limit of quantitation for
pyronaridine of 14.3 ng/ml in urine and 5.7 ng/ml in
blood [92,96].
Pharmacokinetics in animal models
The pharmacokinetics of pyronaridine in rabbit blood
was determined using a spectrofluorometric method for
IG, IM or IV administration [93]. Intragastric pyronari-
dine pharmacokinetics were described using a linear
open two-compartment model. Mean pharmacokinetics
for 30 mg/kg (n = 3) or 60 mg/kg (n = 3) were, respect-
ively: T1/2 56.0 ± 7.0 h, 56.0 ± 7.0 h; Cmax 768 ±
17.0 ng/ml, 1,514 ± 376 ng/ml; and Tmax 1.38 ± 0.22 h,
1.62 ± 0.37. Using the same model as for intragastric ad-
ministration, intramuscular pyronaridine (6 mg/kg)
pharmacokinetics showed complete and rapid absorp-
tion with a ka of 33.54 ± 21.81 h
-1 and a Tmax of 0.75 ±
0.44 h. Intragastric pyronaridine was 34.6% bioavailable
compared with IM administration, with a ka of 2.4 ±
1.26 h-1 [93]. A further study in rabbits of 20 mg/kg IM
pyronaridine had a comparable T1/2 of 49 h and Cmax
was reached within one hour after dosing [4]. Using a
linear three-compartment open model, mean (± SD)
pharmacokinetic parameters after pyronaridine 6 mg/kg
IV bolus (n = 4) were: T1/2 59.0 ± 10.0 h; Vc 2.418 ±
0.287 L/kg; Vd(ss) 29.0 ± 6.0 L/kg; CLT 0.442 ± 0.131 L/
kg.h.
Pyronaridine blood concentrations in rhesus monkey
(n = 1) after oral administration of 160 mg/week for
three weeks were sampled at 0.5 h, then hourly for eight
hours then at Days 1, 2, 3, 7, 14, 21 and 28 [97] Pyronar-
idine blood concentrations after three weeks of 160 mg/
week were undetectable on Weeks 2 and 3. With a
540 mg/week oral dose, pyronaridine concentrations at
Week 3 were 88 ng/ml four hours after dosing and
142 ng/ml at 30 h [97]. With IM administration of
160 mg/kg for three weeks in the same model, the high-
est concentration of pyronaridine was recorded one hour
after the Week 3 dose (1983 ng/ml) [97]. Pyronaridine
concentrations had declined below the limit of detection
by 21 days; the T1/2 was 64 h [97]. Pyronaridine concen-
trations in urine for the 24-h period after Week 2 dosing
after IM administration were approximately 20-fold
higher than with oral dosing [97].
The pharmacokinetics of pyronaridine have been inves-
tigated following single intravenous and oral administra-
tion to the rat and dog [76]. Following intravenous
administration of pyronaridine to rats and dogs, the blood
concentrations of pyronaridine declined in a multi-
exponential manner with an apparent terminal half-life of
2 to 4 days. The total blood clearance was low, at less than
30% hepatic blood flow, and the volume of distribution
was high, indicating extensive distribution to tissues. Oral
bioavailability was calculated to be 42% in the rat and 35%
in the dog. Co-administration of pyronaridine with artesu-
nate (both 10 mg/kg) in the dog reduced the exposure to
pyronaridine by approximately 2-fold following both oral
and intravenous administration.
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Metabolism
In a rhesus monkey given oral or IM pyronaridine
160 mg/week for three weeks, no metabolites were seen
in whole blood, though evidence for at least one metab-
olite was found in urine at a concentration of 100−200
ng/ml in samples collected seven days after dosing [97].
In rats (n = 4), no glutathione conjugates or quinonei-
mine metabolites could be detected in bile samples from
animals given pyronaridine [8].
More recently, in vitro studies in which pyronaridine
was incubated with rat liver microsomes generated 11
different metabolites, whereas incubation with human
liver microsomes generated nine metabolites [90]. Six
metabolites were observed in both rat and human
microsomes, five were only seen in rat and three only in
human microsomes [90]. Subsequent metabolite profil-
ing with [14 C] pyronaridine in rat, dog and human liver
microsomes showed all human in vitro metabolites to be
present in both rat and dog systems, however no struc-
tural identification was attempted because of the low
metabolic turnover [76]. In vivo studies in rats given intra-
peritoneal (IP) pyronaridine 50 mg/kg found 14 different
metabolites in urine and faeces. Unchanged pyronaridine
was excreted mainly in the urine and metabolites in the fae-
ces. Three metabolites were observed only in faeces. Over-
all, across the in vitro and in vivo studies, there were three
main pathways for pyronaridine metabolism: i) aminoqui-
noline conversion to quinoneimine, ii) pyrrolidine ring hy-
droxylation or carbonylation, and iii) O-demethylation.
Quinoneimine metabolites of aminoquinolines are of inter-
est as they are thought to cause the toxicity problems seen
with amodiaquine [98]. However, quinoneimine metabo-
lites were detected only in the microsome studies, not
in urine or bile from in vivo studies. This suggests that,
either the other available metabolic pathways are pre-
ferred, or that these metabolites are easily reduced in vivo.
O-demethylation was detected in rat, but not human
microsomes [90].
Following oral administration of [14 C] pyronaridine to
rat and dog, profiling of plasma, urine, faecal and liver
extracts indicated a single major dose-related compo-
nent, which was confirmed to be unchanged pyronari-
dine. [14 C] pyronaridine was the only component in any
sample that represented >5% of the dose administered,
thus indicating that pyronaridine undergoes no signifi-
cant metabolism in rat and dog [76]. Incubations with
recombinant human CYP450 isoforms indicated that
pyronaridine could be metabolised by CYP1A2, CYP2D6
and CYP3A4 [76].
Distribution and elimination
In vivo data from rabbits indicate that pyronaridine is
concentrated in blood cells with a blood:plasma ratio
ranging from 4.9 to 17.8 with 20 mg/kg IM dosing [4],
and between 3−6 during 1−96 h after 6 mg/kg IM dosing
[93]. In vitro studies using whole blood, indicated that
pyronaridine preferentially associates with blood cells
with a blood:plasma distribution of 2.1 to 2.4 in rat, 2.5
to 3.8 in rabbit, 2.0 to 2.4 in dog and 1.2 to 1.7 in human.
Plasma protein binding of pyronaridine in rat, rabbit, dog
and human was high (92-96%) and similar in all species
[76]. Pharmacokinetic studies using plasma may, there-
fore, underestimate pyronaridine concentrations.
The major sites of pyronaridine distribution in tissues
24 h after IG administration of 3H-pyronaridine 30 mg/
kg to mice were: liver (17.9%), large intestine and con-
tent (1.7%), kidney (1.4%), lung (1.1%), spleen (0.5%) and
stomach and content (0.3%); 0.5% was present in whole
blood and 0.3% in plasma [99]. Recovery from urine and
faeces was 54.3% at 24 h after dosing, and 12.0%
remained in the carcass [99]. For IP administration of
30 mg/kg pyronaridine, 20.3% of the dose was present in
the liver, 3.3% the large intestine, 1.3% kidney, 0.7% lung,
1.2% in spleen and 0.6% in stomach; 0.4% was present in
whole blood and 0.1% in plasma. Residual carcasses con-
tained 20.0% of the dose and 39.6% was excreted in
urine and feces. During 12 days after IG and IP adminis-
tration, the total urinary excretion was 20.83% and
24.07%, and the total faecal excretion was 40.44% and
41.24%, respectively [99].
Quantitative whole body phosphor imaging, following
oral administration of 14 C-pyronaridine to non-
pigmented and pigmented rats showed concentrations of
radioactivity were greater than 10-fold higher in tissues
than in blood. The highest concentrations of radioactiv-
ity were achieved in the liver, spleen, adrenal gland, kid-
ney and thyroid gland, with half-lives of elimination
between 137 and 231 h. There was evidence of melanin
binding in the eye [76].
In rabbits, one hour following IM 2 mg/kg pyronari-
dine, the highest drug concentrations were found in
lung, spleen and kidney (28.6% of dose); peripheral
blood had 2.5% and total recovery was 31.1% [94]. Pyro-
naridine concentrations had significantly decreased in all
tissues 72 h after administration; the highest concentra-
tions were in the spleen, kidney, lung, liver and heart
(5.2% of dose); 0.07% was found in peripheral blood [94].
The pharmacokinetics of 14 C pyronaridine tetrapho-
sphate was studied in male and female Sprague–Dawley
rats. Following oral administration of a single dose
(10 mg/Kg) of 14 C- pyronaridine tetraphosphate [100],
the drug was rapidly adsorbed mainly from the small in-
testine and it was rapidly distributed as evidenced by the
observed radioactivity in all the tissues studied within
one hour of drug administration. The Cmax in the stom-
ach (47.9 and 30.7 μg eq/g) was reached in one hour in
both male and female rats, while in small intestine
(166.3 and 186.1 μg eq/g) it was observed after two
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hours in male rats and four hours in female rats. The
drug was rapidly distributed to various organs with the
Cmax in the liver (186.8 and 189.8 μg eq/g) being
observed by 4.7 h both in male and female rats. The
Cmax in kidney (53.6 and 31.0 μg eq/g), heart (10.1 and
7.9 μg eq/g) and lungs (36.4 and 41.9 μg eq/g) was
reached in seven to 10 h in both male and female rats.
The Cmax in spleen (88.0 and 76.6 μg eq/g) was reached
in 21 h and in brain (6.7 and 8.2 μg eq/g) it was in about
36 h. The low levels of radioactivity observed in the
brain indicate that 14 C- pyronaridine diffuses poorly
through the blood–brain barrier. The radioactivity in all
the tissues gradually decreased to less than 30 μg eq/g
post 48 h of drug administration. Excretion of the drug
was predominantly through the urine with a peak excre-
tion post 24 h of administration. A small amount of the
drug was also excreted in the faeces and also in the
breath [100].
Excretion balance investigations in the rat, following a
single oral dose of [14 C] pyronaridine tetraphosphate at
60 mg/kg, produced an overall recovery of 93% over the
14 day collection period. A mean of 83% of the dose was
excreted in faeces, with 2.6% excreted in urine, 6.3%
recovered from the carcass at 14 days and the remainder
in cage washings [76]. Excretion balance investigations
in the dog, following a single oral dose of [14 C] pyronar-
idine tetraphosphate at 9 mg/kg, produced an overall re-
covery of 44% over the 14 day collection period. A mean
of 36% of the dose was excreted in faeces, with 5.5%
excreted in urine. The shortfall in recovery was investi-
gated and a significant proportion of the dose was found
to remain associated with the liver. The liver removed
from a single animal at 6 months post-dose contained
14.3% of administered radioactivity. Other tissues con-
tained considerably less, with the kidney being the next
highest with 0.3% of administered radioactivity at
6 months post-dose [76]. Further sampling of dog liver
showed a slow but steady decline in the concentration of
radioactivity with 6.5% of administered radioactivity
remaining in the liver at 24 months post-dose [76]. Pro-
filing of liver extracts indicated a single major dose-
related component, which was confirmed to be un-
changed pyronaridine [76].
Clinical pharmacokinetics
Some data are available regarding the clinical pharmaco-
kinetics of pyronaridine derived from HPLC plasma
assays in volunteers and patients [6,95,101]. Oral admin-
istration of 400 mg pyronaridine (6.15 mg/kg) to one
healthy volunteer gave a Cmax of 76.2 ng/ml at a Tmax
of one hour. The area under the curve (AUC(0−12)) was
662.9 ng.h/ml [101]. The drug was poorly absorbed from
the tablet formulation used and drug levels were below
the lower limit of quantitation by 24 h after dosing
(Limit of detection = 25 ng/mL) and half-life was not
estimated. [101]. A further study of pyronaridine as a
single oral dose (400 mg) given to a healthy volunteer
found a Cmax in plasma of 495.8 ng/ml at a Tmax of
0.5 h. The T1/2 was 241 h, the AUC(0−∞) 51,700 ng.h.ml,
clearance (CLT) 1.90 ml/min/kg and volume of distribu-
tion 41.2 L/kg [95]. In five Thai patients with uncompli-
cated malaria receiving a three-day course of oral
pyronaridine tetraphosphate as a new capsule formula-
tion 12 mg/kg the Cmax in plasma was 120 ± 30 ng/ml,
Tmax was 80.0 ± 79.9 h and the AUC0−∞ 29,400 ±
13,100 ng.h/mL. Pyronaridine after repeat dosing was
eliminated from plasma with a mean half-life of 194.8 ±
47.8 h [6]. Plasma pyronaridine profiles, in contrast to
blood level profiles, do not show clear distribution and
elimination profiles and thus, half-life determinations
based upon plasma data may not be strictly comparable
to half-lives determined from blood level data.
As pyronaridine concentrates in erythrocytes
[4,32,38,93], plasma assays may underestimate pyronari-
dine concentrations. The pharmacokinetics of pyronari-
dine in blood have been investigated in patients with P.
falciparum or P. vivax malaria using a spectrofluoro-
metric assay. [102]. Intramuscular pyronaridine 206 mg
(n = 4) was rapidly absorbed; mean (± SD) Cmax was
525 ± 104 ng/ml at Tmax 0.66 ± 0.21 h and the T1/2α
was 1.0 ± 0.3 h and T1/2β was 63 ± 5 h. Distribution in
tissues was extensive; Vc was 11 ± 11 L/kg, Vd(SS) 72 ±
33 L/kg and CLT 0.9 ± 0.35 L/kg.h. The relative bioavail-
ability of two oral formulations (600 mg) was 19 ± 7%
for enteric-coated tablets (n = 3) and 32 ± 7% for cap-
sules (n = 3) [102]. Pyronaridine pharmacokinetics for
the tablets and capsules were, respectively: Cmax 130 ±
32, 255 ± 144 ng/ml; Tmax 14.0 ± 0.3, 4.72 ± 0.26 h; T1/
2β 65 ± 6, 63 ± 6 h; and CLT 0.796 ± 0.002, 0.71 ±
0.14 kg/L.h [102]. Since blood sampling was only over
72 h, it is probable that T1/2β was underestimated in this
study.
The population pharmacokinetics of pyronaridine in
healthy and malaria infected subjects with uncompli-
cated falciparum and vivax malaria after the administra-
tion of oral pyronaridine/artesunate (3:1 ratio) have been
published as an abstract [103]. Pyronaridine blood con-
centrations were measured in nine Phase I-III clinical
studies using HPLC and LCMS methods with LLOQ
5.7 ng/mL. The population pharmacokinetics are
reported using data from healthy (166) and malaria
infected (642) subjects. Pyronaridine pharmacokinetics
data were best described by a two-compartment model
with first order absorption and elimination. Malaria in-
fection was a significant covariate for central volume of
distribution and clearance. Body weight was a significant
covariate for peripheral volume of distribution and clear-
ance. After the inclusion of statistically significant
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covariates, the population parameter estimates of appar-
ent clearance, central volume of distribution, peripheral
volume of distribution, apparent inter- compartmental
clearance and absorption rate constant (Ka) were 434 L/
day, 907 L, 4,430 L, 1,120 L/day and 16.7 day-1, respect-
ively. The corresponding inter-individual variability esti-
mates for CL/F, V2/F, V3/F, Q/F and Ka were 53.6%,
103%, 29%, 28.8% and 67.5%, respectively. The elimin-
ation half-lives of pyronaridine in healthy adult subjects,
adult malaria subjects were estimated to be 11.3 and
13.2 days, respectively.
Clinical pharmacokinetics in children
Pharmacokinetic characteristics of pyronaridine, artesu-
nate, and dihydroartemisinin were evaluated in a clinical
study with tablet (6 + 2 mg/kg, 9 + 3 mg/kg, 12 + 4 mg/kg
pyronaridine + artesunate respectively) and granule
(9 + 3 mg/kg) formulations in Gabonese children aged
two to 14 years [104]. Pyronaridine drug concentrations
similarly increased in a dose dependent pattern: Cmax
and AUC rose from 85.7 ng/ml to 338.5 ng/ml and
17,623 to 35,360 ng/ml*hr, respectively. Tmax was be-
tween 2.4 and 3.2 h and the elimination half-life ranged
between 6.6 and 9.0 days. Based upon population phar-
macokinetic modeling, the elimination half-life of pyro-
naridine in pediatric malaria subjects was estimated to
be 9.6 days (103). Artesunate is rapidly converted to
dihydroartemisinin in vivo. Mean Cmax and AUCINF
levels for artesunate increased dose dependently from
92.8 ng/ml to 287.0 ng/ml and 104.3 to 232.3 ng/ml*hr,
respectively. Tmax was within a range of 0.5 to 1.0 h and
t1/2 was between 0.5 to 1.2 h. Dihydroartemisinin
showed a linear increase in Cmax from 479.1 to
1,185.9 ng/ml and AUC values from 1,054.5 to
2,961.0 ng/ml*hr. The time to maximal drug concentra-
tions was between 1.3 and 1.7 h after drug administration.
Dihydroartemisinin showed a relatively short half-life of 0.9
to 1.2 h in the respective treatment groups. Pharmacoki-
netic parameters of the granule paediatric co-formulation
were compared with the respective tablet formulation of
the same dose strength (3 mg/kg artesunate and 9 mg/kg
pyronaridine). There were no statistically significant dif-
ferences in pharmacokinetic parameters except for a
higher Cmax of pyronaridine in the patient group receiv-
ing the paediatric drug formulation (168.3 ng/ml versus
118.5 ng/ml; p <0.05).
Clinical efficacy
Monotherapy in falciparum malaria
Adults
Pyronaridine was approved for human use in China in
1980 at a total oral dose of 1,200 mg (or 24 mg/kg)
divided into two doses on Day 0 and one dose on each
of the following one or two days. Intramuscular or IV
pyronaridine was given as 300 mg (or 6 mg/kg) divided
into two doses eight hours apart. The main clinical stud-
ies of oral, IM and IV pyronaridine monotherapy con-
ducted in China have been reviewed in English by Fu
and Xiao and Shao and are summarized in Additional
file 5 [5,79,105]. The pyronaridine IM dose was later
increased to 480 mg (or 9.6 mg/kg) divided into three
doses once daily for three days for the treatment of
chloroquine-resistant P. falciparum; no cases of recru-
descence were seen in 10 patients after 30 days of follow
up [3,71,106]. Plain tablet and enteric-coated tablet oral
formulations were also tested in different dosage regi-
mens (Additional file 5) [105]. Anecdotally, pyronaridine
was used successfully to treat at least 40 cases of cere-
bral malaria or malaria in late pregnancy [3].
Outside China, two clinical trials of oral pyronaridine
for the treatment of falciparum malaria have been
reported in adults: one randomized trial in Cameroon in
comparison with chloroquine and one in Thailand com-
paring two doses of pyronaridine (Additional file 6)
[57,107]. One retrospective report using data from the
Cameroon studies has also been published [108]. In
addition, a case study from Indonesia reported radical
cure of multidrug-resistant falciparum malaria with pyr-
onaridine 1,200 mg with no recrudescence at Day 28
after failure of chloroquine and mefloquine [109].
The efficacy of pyronaridine monotherapy in uncom-
plicated falciparum malaria was compared with that of
chloroquine in a randomized open-label study con-
ducted in Cameroon (Additional file 6) [107]. Adult
patients received either pyronaridine 32 mg/kg (n = 40)
or chloroquine 25 mg/kg (n = 41) given in four divided
doses over three days (two doses on Day 0). The clinical
response at Day 14 was 100% for pyronaridine versus
58.5% for chloroquine (P= 0.0001). All patients receiving
pyronaridine had a negative parasite count on or before
Day 3 or positive on Day 3, but <25% of pre-treatment
density plus negative there after until Day 14 compared
with 18/41 (43.9%) of chloroquine-treated patients. Four
cases of chloroquine failure required treatment with an
alternative anti-malarial on or before Day 3. There was
no significant difference in parasite clearance or fever
clearance times between treatment groups for those
patients that had a successful clinical and parasitological
response (Additional file 6) [107]. The IC50 for pyronari-
dine against 67 P. falciparum clinical isolates tested was
4.82 nM, 6.7-fold more active than chloroquine against 30
chloroquine-sensitive isolates (IC50 32.5 nM) and 73-fold
more active than chloroquine against 39 chloroquine-
resistant isolates (IC50 354 nM) [107].
Looareesuwan et al. evaluated the efficacy of two dos-
ing regimens of pyronaridine in a non-randomized,
open-label study of 101 adult Thai patients with uncom-
plicated falciparum malaria (Additional file 6) [57].
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Patients received either 1,200 mg in four divided doses
over three days, two doses on Day 0 (n = 69) or
1,800 mg in six divided doses over five days, two doses
on Day 0 (n = 32). Based on the mean weight of subjects
enrolled, the 1,200 mg dose given in the Thailand study
is equivalent to a mean dose of 25.7 mg/kg and the
1,800 mg dose to a mean dose of 36.4 mg/kg. Clinical
success at Day 28 was achieved in 38/60 (63.3%) evalu-
able patients for the 1,200 mg dose and 23/26 (88.4%)
for the 1,800 mg dose (P < 0.025). Recrudescence oc-
curred between Days 13 and 28 (median 24 days) in the
1,200 mg group and between Days 11 and 28 (median
17 days) in the 1,800 mg group. Sixteen patients in the
1,200 mg group and 11 in the 1,800 mg group had at
least one parasite count greater than their initial count
[57]. There were no significant differences in time to
clear fever or parasites between the two treatment
groups (Additional file 6) [57]. The time to clear 50%
and 90% of parasites were 68 h and 152 h for the
1,200 mg group and 70 h and 120 h for the 1,800 mg
group, respectively. The pyronaridine mean pre-
treatment IC50 for 10 patients that were cured was 15.69
± 3.82 nM compared with 22.98 ± 12.1 nM in 10
patients who had recrudescence. The authors suggested
that there was a relationship between treatment result
and parasite sensitivity to pyronaridine. However, there
was no evidence of the development of resistance after
unsuccessful treatment with pyronaridine: the initial pyr-
onaridine mean IC50 was 23.39 ± 12.71 nM versus 22.96
± 11.54 nM after recrudescence in P. falciparum isolates
from nine patients for whom paired data were available
[57].
In contrast to the Cameroon study, recrudescences
were seen in Thailand; fever clearance and parasite clear-
ance times were also extended by 47.9−50.5 h and 7.6
−9.9 h, respectively [57,107]. These differences in efficacy
between Cameroon and Thailand were not unexpected.
In this region of Thailand the high frequency and degree
of resistance to chloroquine, sulphadoxine and pyrimeth-
amine and the high prevalence of multi-resistant P. fal-
ciparum, even in the mid-1990s, presented a difficult
challenge for new therapy [110]. The 88% cure rate for
the 1,800 mg dose of pyronaridine compares favourably
with contemporary anti-malarial monotherapy studies
also conducted at the Bangkok Hospital for Tropical Dis-
eases: 88% for artesunate (600 mg/5 days), 74% for oral
artemether (500 mg/5 days) and 81% for mefloquine
(1250 mg) [57]. In Cameroon, Day 28 recrudescence
rates around the time of the study were reported as 22/
131 (16.8%) for chloroquine, 4/66 (6.1%) for sulphadox-
ine−pyrimethamine and 0/59 for amodiaquine [108].
When comparing IC50s obtained in the two clinical stud-
ies, pyronaridine was 3.3-fold more active against Camer-
oon isolates than against those from Thai patients that
were cured and 4.8-fold more active against those from
Thai patients who had recrudescence [57,107].
Children
One study of oral pyronaridine for the treatment of un-
complicated falciparum malaria in children has been
conducted in Cameroon (Additional file 6) [111].
Patients were aged between five and 15 years old with a
mean parasitaemia of 103,000 asexual parasites/μL of
blood (range 7590−609,600 parasites/μL). All 41 patients
receiving pyronaridine (32 mg/kg, four divided doses,
two on Day 0) were clinically and parasitologically cured
at Day 7 and Day 14. Chloroquine 25 mg/kg (10 mg/kg
Day 0 and 1, 5 mg/kg Day 2) was significantly less effect-
ive than pyronaridine for both clinical response
(P= 0.001) and parasitological response at Day 14
(P= 0.0001). In the chloroquine group, 5/40 (12.5%)
patients required alternative anti-malarial therapy on or
before Day 3. There was no significant difference in
fever or parasite clearance times between the two ther-
apies in those patients that had a successful clinical and
parasitological response (Additional file 6) [111]. The
geometric mean IC50 of pyronaridine was 6.89 nM
(n= 25, range 1.95−34.2 nM) for patients treated with
pyronaridine and 5.69 nM (n = 27, range 0.8−16.6 nM)
for those who received chloroquine. For patients in the
pyronaridine group, 23/40 (57.5%) of the isolates tested
were chloroquine-resistant (chloroquine IC50 >100 nM).
Clinical and parasitological efficacy of pyronaridine was
demonstrable against all of these chloroquine-resistant
isolates.
Combination therapy in falciparum malaria
Pyronaridine plus sulphadoxine−pyrimethamine or sul-
phadoxine−primaquine
Based on in vitro data and clinical studies, the use of
pyronaridine in combination therapy was recommended
in China for use in areas of endemic chloroquine-
resistant P. falciparum [56,66,71,112-116]. Additional
file 7 summarizes the clinical studies conducted in China
for pyronaridine−sulphadoxine−pyrimethamine and pyr-
onaridine−sulphadoxine−primaquine in Hainan and
Yunnan Provinces, respectively [66,71].
A small study (n = 101) was conducted in Hainan
province, China, where chloroquine resistant P. falcip-
arum is endemic, where patients with acute symptom-
atic falciparum malaria were treated sequentially with
pyronaridine−sulphadoxine−pyrimethamine orally, with
one of three dosage regimens (Additional file 7) [66].
The combination cleared fever in 30.1−38.4 h and
parasitaemia within 41.9−48.7 h; there were no recru-
descences within four weeks after therapy (Additional
file 7) [66].
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Pyronaridine plus nitroquine
Pyronaridine plus nitroquine was also studied in Hainan;
comparators included pyronaridine or piperaquine
monotherapy and piperaquine plus nitroquine [117].
There was no improvement with pyronaridine/nitro-
quine combination therapy in recrudescence rates, or
times to fever and parasite clearance versus pyronaridine
monotherapy (Additional file 7) [117].
Pyronaridine plus artemisinin derivative
combination therapy
Pyronaridine plus dihydroartemisinin
A double-blind study in China investigated the efficacy
of pyronaridine (1600 mg, n = 25) or dihydroartemisinin
(DHA, 640 mg, n = 24) alone or in combination
(800 + 300 mg, n = 32) in uncomplicated falciparum mal-
aria (Additional file 7) [118]. The recrudescence rate at
Day 28 was 0% for pyronaridine 4.2% for DHA and 0%
for the combination. Fever resolution was significantly
more rapid with the combination (35.7 ± 24.7 h) than
with DHA alone (52.6 ± 38.9 h, P < 0.01). Time to para-
site clearance was significantly faster with the combin-
ation (23.8 ± 10.1 h) than with pyronaridine alone (49.4
± 20.3 h, P < 0.01). Gametocyte carriage was 20.0% for
the combination, 16.7% for DHA alone and 60.9% for
pyronaridine alone, which was significantly higher than
for the combination (P < 0.01) [118]. These early results
showed promise for pyronaridine combination therapy
with artemisinins and indicated that a lower dose of
both compounds could be used effectively versus the
monotherapy doses.
Pyronaridine plus artesunate combination: tablet
formulation
Pyronaridine-artesunate has been developed as a fixed-
dose combination therapy by Shin Poong Pharmaceutical
Ltd, South Korea, with the tetraphosphate pyronaridine
salt in a 3:1 ratio with artesunate as an oral once daily
treatment for three days, for uncomplicated P. falcip-
arum malaria and for the blood stages of P. vivax malaria
in adult and paediatric patients. A conference report is
available for a double-blind, multicentre, randomized
Phase II study including 477 adults in Africa and SE
Asia [119].
One Phase II study, conducted in Gabon, has been
reported [104]. Two fixed-dose pyronaridine-artesunate
formulations (tablets and granules) were compared in
children (two to 14 years old) for the treatment of un-
complicated falciparum malaria. An open-label dose es-
calation study design was used, recruiting 15 patients
sequentially in each of four treatment cohorts. The com-
bination was administered once daily for three days as
co-formulated tablets at the following dose levels:
2:6 mg/kg, 3:9 mg/kg, and 4:12 mg/kg artesunate and
pyronaridine, respectively. Additionally, a paediatric
granule co-formulation was investigated at the medium
dose strength (3:9 mg/kg) in a fourth cohort. The com-
bination showed a good tolerability profile at all dose
levels and there were no safety concerns. Pharmacoki-
netic analysis revealed a dose dependent increase in
Cmax and AUC values and a comparable relative bio-
availability of the granule co-formulation. At all dose
levels efficacy of pyronaridine artesunate combination
therapy was 100% in the per protocol analysis on Day 28
after PCR correction [104].
A Phase III programme with fixed-dose pyronaridine-
artesunate included four phase III pivotal studies; two
studies in adults and children in P. falciparum malaria
versus artemether-lumefantrine in one study and meflo-
quine + artesunate in the other study, one study in adults
and children in P. vivax malaria versus chloroquine
[120] and one study in children only in P. falciparum
malaria with the granule formulation versus artemether-
lumefantrine. Overall, in the clinical programme, a total
of 2,815 patients were treated with pyronaridine-artesu-
nate, including 1,528 adults (≥ 18 years), 401 patients
12–18 years and 886 children (< 12 years) [120].
Pyronaridine-artesunate showed high levels of efficacy in
adults and children malaria patients. In both populations
pyronaridine-artesunate and the comparator drugs were
well tolerated. The rate and type of adverse event were
generally comparable between the various treatment
groups and were of mild or moderate severity [104,120].
A pivotal, multicentre, randomized, comparative,
parallel group, double-blind, double-dummy study
compared the efficacy and safety of once a day
pyronaridine-artesunate with twice a day lumefantrine-
artemether in uncomplicated P. falciparum malaria in
children and adults [121]. A total of 1,272 patients were
randomized to treatment, 84.9% from Africa and 15.1%
from Asia. For the primary endpoint, Day-28 PCR--
corrected adequate clinical and parasitological response
(ACPR) in the per protocol population, pyronaridine-
artesunate was non-inferior to lumefantrine-artemether.
Both treatments were highly efficacious with cure rates
>99% and no early clinical failures. These results are
consistent with the high activity observed for
pyronaridine-artesunate against African P. falciparum
isolates and 100% cure rates from the previous
pyronaridine-artesunate clinical study [104]. Day-28
crude ACPR (per protocol population) and Day-42 PCR-
corrected and crude ACPR (per protocol and intent to
treat population) were superior with pyronaridine-
artesunate versus lumefantrine-artemether. Kaplan–
Meier analysis confirmed an important difference in re-
infection rate between treatment groups through Day 28
and 42. Parasite clearance was more rapid with
pyronaridine-artesunate versus lumefantrine-artemether
Croft et al. Malaria Journal 2012, 11:270 Page 19 of 28
http://www.malariajournal.com/content/11/1/270
(p < 0001), with the greatest difference seen before Day
2. There was no difference in fever clearance time be-
tween the treatment groups.
A further pivotal, multicentre, randomized, compara-
tive, parallel group, open-label study compared
pyronaridine-artesunate and a loose combination of mef-
loquine + artesunate in uncomplicated P. falciparum
malaria in children and adults. Overall, 1,271 patients
were included in the study, 81% from Asia, 19% from
Africa. Day-28 PCR-corrected ACPR in the per protocol
population were 99.2% for pyronaridine-artesunate and
98.1% for mefloquine + artesunate. Pyronaridine-
artesunate was non-inferior to mefloquine + artesunate;
treatment difference 1.1% (95% CI −0.2, 3.1; p = 0.106).
ACPR were ≥ 95.7% across individual study centers for
both study treatments. In 211 patients in the region of
Cambodia where extended parasite clearance times are
reported, parasite clearance time for both treatments
was prolonged compared with other countries (P < 0.001,
Kaplan–Meier); median time to parasite clearance was
twice as long (64 versus 31–32 hours) [122].
Pyronaridine plus artesunate combination: paediatric
formulation
A phase III comparative, double-blind, double dummy,
randomized, non-inferiority, multicentre clinical study
was conducted in paediatric patients to assess the efficacy
and safety of a granule fixed dose formulation of oral
pyronaridine-artesunate (60:20 mg) versus artemether-
lumefantrine tablet (20:120 mg) in 535 patients (mean
5.0 years (0 to 12 years); mean 16.6 kg (6–24.9 kg)) with
acute uncomplicated P. falciparum malaria. Patients from
seven sites in Africa and South East Asia were randomized
to receive a three-day course of either pyronaridine-
artesunate once a day or artemether-lumefantrine twice
a day [121]. In the per protocol population, the PCR-
corrected ACPR was 97.6% and 98.8% at Day 28 and
79.5% and 82.6% at Day 42 with pyronaridine-artesunate
and artemether-lumefantrine respectively. Results dem-
onstrate non-inferiority of pyronaridine-artesunate to
artemether-lumefantrine at Day 28 with a treatment dif-
ference −1.2% (95% CI −3.6, 2.1; p = 0.373). The crude
ACPR was 90.2 and 89.2 at Day 28 (non-inferiority) and
77.4% and 80.2% at Day 42 with pyronaridine-artesunate
and artemether-lumefantrine (non-inferiority), respect-
ively. Median time until parasite clearance was 24.1 h
and 24.2 h for pyronaridine-artesunate and artemether-
lumefantrine respectively [121].
Non-falciparum malaria
Plasmodium ovale and Plasmodium malariae malaria
Pyronaridine efficacy was investigated in 22 patients with
P. ovale (n = 10) and/or P. malariae infection (n =16) in
Cameroon [74]. Mean fever and parasite clearance times
were 49.8 h and 33.5 h, respectively. All patients were
apyretic by Day 4 and all had clinical and parasitological
cure at Day 14 [74]. No gametocytes were found on Day
3 [74].
Plasmodium vivax malaria
Pyronaridine has been evaluated both alone and in com-
bination with primaquine for efficacy against P. vivax
(Additional file 8) [5,79,123,124]. The efficacy of pyro-
naridine 1200 mg over three days oral monotherapy
against P. vivax was similar to that of chloroquine [79].
Intramuscular pyronaridine results in marginally faster
parasite clearance than with oral and IV administration.
Pyronaridine has also been evaluated in combination
with short-course (three- or four-day) primaquine
[123,124]. It had acceptable efficacy, though comparator
regimens including primaquine for eight days were the
most effective among those tested at preventing relapse
(Additional file 8) [123,124].
The fixed dose pyronaridine-artesunate combination
tablet has been tested as an oral once daily treatment
over three days for blood stage of P. vivax malaria [125].
A pivotal phase III multicentre, randomized, double-
blind, double-dummy, parallel-group comparative, non-
inferiority trial was conducted for curative treatment of
P. vivax malaria. The primary objective of this clinical
study was to compare the efficacy and safety of the fixed
combination of pyronaridine-artesunate with that of
standard chloroquine therapy in adults and children with
acute, uncomplicated P. vivax malaria. This trial
included five centres across Cambodia, Thailand, India,
and Indonesia. In a double-dummy design, patients
(aged >3–≤60 years) with microscopically confirmed P.
vivax mono-infection were randomized (1:1) to receive
pyronaridine-artesunate (target dose 7.2:2.4 mg/kg to
13.8:4.6 mg/kg) or chloroquine (standard dose) once
daily for three days. For patients who completed the
study up to Day 28 and who had normal glucose-6-
phosphate dehydrogenase activity, a 14-day course of
primaquine (15 mg/day) was administered starting on
Day 28, to complete their radical cure. Each treatment
group included 228 randomized patients. Outcomes for
the primary endpoint, Day-14 cure rate in the per-
protocol population, were 99.5%, with pyronaridine-
artesunate and 100% with chloroquine. Pyronaridine was
non-inferior to chloroquine: treatment difference −0.5%
(95% CI −2.6, 1.4), i.e. the lower limit of the two-sided
95% CI for the treatment difference was greater than
−10%. Pyronaridine-artesunate cure rates were non-inferior
to chloroquine for Days 21, 28, 35 and 42. Parasite clear-
ance time was shorter with pyronaridine-artesunate (me-
dian 23.0 h) versus chloroquine (32.0 h; p <0.0001), as was
fever clearance time (median 15.9 h and 23.8 h, respectively;
p= 0.0017). Kaplan-Meier estimates of post-baseline P.
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falciparum infection incidence until Day 42 were 2.5% with
pyronaridine-artesunate, 6.1% with chloroquine (p=0.048,
log-rank test). Post-baseline P. vivax or P. falciparum infec-
tion incidence until Day 42 was 6.8% and 12.4%, respect-
ively (p=0.022, log rank test) [125].
Pyronaridine plus artesunate combination: pooled
analyses
Integrated analysis of efficacy were performed on pooled
data from the four Phase III pivotal studies; the Phase III
clinical efficacy database included 1,701 patients from
Asia and 1,833 patients from Africa [120].
In each of the three Phase III P. falciparum studies,
non-inferiority of pyronaridine-artesunate versus the com-
parator (i.e., artemether-lumefantrine or mefloquine+
artesunate) was demonstrated as primary endpoint for
PCR-corrected ACPR on Day 28 (per protocol and ITT
populations). The percentage of subjects with gametocytes
gradually decreased to zero or near zero over time in the
pyronaridine-artesunate, mefloquine+ artesunate and
artemether-lumefantrine treatment groups.
In the study in subjects with P. vivax malaria, non-
inferiority of pyronaridine-artesunate compared with
chloroquine was demonstrated with respect to the crude
cure rate on Day 14 (per protocol population). Non-
inferiority was also demonstrated for both PCR-
corrected and crude ACPR at all time points (for both
PP and ITT populations).
Pyronaridine-artesunate showed high levels of efficacy
in P. falciparum and P. vivax adults and children malaria
patients and similar efficacy was observed in Asia and
Africa. Pyronaridine-artesunate showed high cure rates,
similar to those of the current standard of care therap-
ies, along with rapid clearance of parasitaemia and most
malaria-related symptoms, coupled with prevention of
recrudescence. The relatively long half-life of pyronari-
dine could explain the observed prophylactic effect up to
D42 [120].
Tolerability
Pyronaridine monotherapy
Studies in China found pyronaridine to be generally well
tolerated; around 38% of patients experienced adverse
events versus 56% for chloroquine [79]. Adverse events
following oral administration were mild and usually
resolved within two days of starting therapy. The most
common adverse events after oral pyronaridine therapy
in many cases are similar to the symptoms of malaria, ie
dizziness, nausea, vomiting and abdominal discomfort
[79]. There were also some reports of palpitations and
allergic skin reaction [3]. Transient ECG changes have
also been noted at higher pyronaridine doses [3,5]. There
is some evidence that tolerability was improved with a
plain tablet formulation at an 8 mg/kg total dose (5 mg/
kg Day 0, 3 mg/kg Day 2) versus an enteric-coated tablet
at 12 mg/kg (4 mg/kg bid Day 0, 4 mg/kg Day 2); 18.8%
(6/32) and 28.1% (9/32) patients experienced an adverse
event, respectively.
Gastrointestinal effects were mostly absent after IM
administration, though there was some local injection-
site irritation without necrosis. Intravenous administra-
tion was mostly without adverse effects, though nausea,
palpitation, diarrhoea and abdominal pain were noted in
a few patients [79]. At least 10 pregnant malaria patients
were treated successfully with pyronaridine during their
mid- to late-trimester with no known adverse effects [5].
There were some differences in the adverse event pro-
file for pyronaridine monotherapy between trials con-
ducted in Cameroon and Thailand (Additional file 9)
[57,107]. The most common treatment emergent adverse
events reported in African adults were abdominal pain
(32.5%), diarrhoea (25.0%) and pruritus (17.5%) and in
Thailand were headache (36−38%), dizziness (28−33%)
and nausea (11−13%). Pruritis is a known adverse reac-
tion seen in African patients to many anti-malarials, par-
ticularly chloroquine. The incidence of pruritus with
chloroquine was approximately 2.5x that of pyronaridine
in the Cameroon study [107]. A small study in Camer-
oon in patients with P. malariae or P. ovale infection
also reported pruritis with pyronaridine in 3/20 (15.0%)
patients, and 9/20 (45.0%) had mild gastrointestinal
symptoms [74].
In the Cameroon study, haemoglobin was below 8 g/
dL on Day 7 in one patient treated with pyronaridine
and three receiving chloroquine [107]. Serum transami-
nases were increased versus baseline in seven patients
treated with pyronaridine and four treated with chloro-
quine, values were normal by Day 14 in all cases. Total
bilirubin was slightly elevated in five patients receiving
pyronaridine on Day 7 [107].
In the Thailand study, one patient receiving 1,200 mg
pyronaridine and six receiving 1,800 mg pyronaridine
had increased transaminases at Day 7; all cases resolved
within four to five weeks after therapy start [57]. There
were no other laboratory changes of note.
In a study conducted in Cameroon, the most common
treatment emergent adverse events with pyronaridine in
children (n = 41) were abdominal pain (22.0%), diarrhoea
(12.2%) and headache (9.8%) (Additional file 9) [111].
Pruritis occurred in 4.9% of patients receiving pyronari-
dine versus 47.5% of those receiving chloroquine
(n = 40). Between Days 0 and 7 there were significant
(P < 0.05) decreases in mean neutrophils, total bilirubin,
conjugated bilirubin and blood urea and significant
increases in mean lymphocytes, eosinophils, reticulo-
cytes and platelets in both the pyronaridine and
chloroquine-treated groups [111]. These changes were
similar between the two treatment groups. There was no
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significant variation in mean values for haemoglobin,
white blood cell count (WBC), serum transaminases, al-
kaline phosphatase or serum creatinine in either treat-
ment group [111]. There was an inversion of the
neutrophil:lymphocyte differential count with both pyro-
naridine and chloroquine by Day 7, though little change
inWBC. In some patients, the absolute eosinophil count
increased approximately four-fold with both pyronari-
dine and chloroquine. There was no evidence that pyro-
naridine inhibits erythropoiesis or WBC maturation.
Three children receiving pyronaridine had two to three-
fold increases in serum aspartate aminotransferases on
Day 7 versus baseline [111].
Artemisinin-based combination therapy
Pyronaridine plus dihydroartemisinin
In a small study of pyronaridine (32 mg/kg, n = 25) or
DHA (6 mg/kg, n = 20) alone or in combination (16/
6 mg/kg, n = 32) there were no serious adverse events in
any group [118]. Mild headache and nausea were
observed in all three treatment groups. No changes in
blood chemistry and urinalysis were observed. All ad-
verse events disappeared one to two days after the end
of treatment [118].
Pyronaridine plus artesunate combination: tablet
formulation
A Phase II study in adults with P. falciparum malaria
investigated the safety of fixed dose pyronaridine artesu-
nate at three doses: 6 + 2 (n = 160), 9 + 3 (n = 157) or
12 + 4 mg/kg (n = 159) and limited data have been
reported in abstract form [119].
In the Phase III pivotal, multicentre, randomized, com-
parative, parallel group, double-blind, double-dummy study
in a total of 1,272 patients the efficacy and safety of once a
day pyronaridine-artesunate with twice a day lumefantrine-
artemether in uncomplicated P. falciparum malaria in chil-
dren and adults were compared [121]. Safety findings with
pyronaridine-artesunate were generally consistent with the
safety profile for pyronaridine and artesunate given as
monotherapy in Africa and Thailand Similar proportions of
patients experienced at least one adverse event in both
treatment groups; 60% for pyronaridine-artesunate and 57%
for lumefantrine-artemether. Adverse events thought by the
investigator to be treatment-related occurred in a similar
proportion of pyronaridine-artesunate-treated (32.4%) and
lumefantrine-artemether-treated (29.1%) patients. There
were no deaths during the study. Serious adverse events
were reported for 3 [0.4%] subjects receiving pyronaridine-
artesunate, and 2 [0.5%] subjects receiving lumefantrine
artemether, none of which was considered by the investiga-
tor to be related to study drug. The only safety finding
requiring further investigationwas transient increases in hep-
atic enzymes with pyronaridine-artesunate; more patients
experienced >3ULN rises in ALT±AST. However, these
were accompanied in two cases only by a rise of bilirubin
>2ULN and without a concomitant significant rise in alka-
line phosphatase. Values for AST and ALT were close to or
within normal limits by Day 28.
In the pivotal, multi-centre, randomized, comparative,
parallel group, open-label study comparing pyronaridine-
artesunate and mefloquine + artesunate, 1,271 patients
were included. Similar proportions of patients experi-
enced at least one adverse event in both treatment
groups; 45.9% for pyronaridine-artesunate and 44.9% for
mefloquine + artesunate [122]. Adverse events occurring
in > 5% of patients were headache and myalgia with
pyronaridine-artesunate and headache and dizziness with
mefloquine + artesunate. Adverse events thought by the
investigator to be treatment-related occurred in a similar
proportion of pyronaridine-artesunate-treated (18.0%)
and mefloquine + artesunate-treated (22.2%) patients.
Adverse events occurring in > 2% of patients were head-
ache and increased alanine aminotransferase with pyro-
naridine-artesunate, and headache, dizziness and
anaemia with mefloquine + artesunate. There were no
deaths during the study. Serious adverse events were
reported for six (0.7%) patients receiving pyronaridine-
artesunate and three (0.7%) receiving mefloquine + arte-
sunate. Only two serious adverse events, both in the
mefloquine+ artesunate group, were considered treatment-
related by the investigator; convulsion and grand mal con-
vulsion. There were no clinically concerning changes in
haematology parameters during the study and no differ-
ences between treatment groups. Mean alanine amino-
transferase was increased in the pyronaridine-artesunate
group at Day 3 (+6.4 U/L) and Day 7 (+12.8 U/L). Three
pyronaridine-artesunate-treated patients had peak alanine
aminotransferase≥3 times the upper limit of normal
(ULN) plus peak bilirubin ≥2 ULN; one patient also had
aspartate aminotransferase ≥3 ULN at Day 42. Alanine
aminotransferase and aspartate aminotransferase values
were within normal limits by Day 28 for one subject; peak
values were at the final recorded evaluation for the other
two subjects. Other clinical chemistry values were similar
between treatment groups.
The fixed dose pyronaridine-artesunate combination tab-
let has been tested as an oral once daily treatment for three
days for blood stage of P. vivax malaria in a pivotal Phase
III multi-centre, randomized, double-blind, double-dummy,
parallel-group comparative, non-inferiority trial [125]. In
the pyronaridine-artesunate group, 92/228 (40.4%) patients
experienced a treatment-emergent adverse event of any
cause compared with 72/228 (31.6%) in the chloroquine
group. Increased transaminases were more common in the
pyronaridine-artesunate group (2.2%) versus the chloro-
quine group (0%). All adverse events in the pyronaridine-
artesunate group and the majority (70/72; 97.2%) in the
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chloroquine group were of mild-to-moderate severity. Ad-
verse events deemed study drug related by the investigator
occurred in 27/228 (11.8%) patients in the pyronaridine-
artesunate group and 23 (10.1%) in the chloroquine group.
There were no deaths during the study. Two patients, both
in the pyronaridine-artesunate group, had serious adverse
events (one pyrexia, one typhoid fever); neither was consid-
ered drug related by the investigator. Two patients, both in
the chloroquine group, had adverse events leading to drug
discontinuation and study withdrawal (one vomiting plus
fatigue, one vomiting); all considered possibly related to
drug treatment by the investigator. No clinically meaningful
difference in change from baseline in haemoglobin was
observed between patients with or without phenotypic
G6PD deficiency. Other haematology laboratory findings
(increases in platelets, eosinophils, and lymphocytes and a
decrease in neutrophils) were of similar magnitude in both
treatment groups. Biochemistry laboratory observations
were generally similar in both treatment groups, with the
exception of alanine transaminase (ALT) and aspartate
transaminase (AST). From Day 3 to the end of the study,
3/228 (1.3%) patients in the pyronaridine-artesunate group
had peak ALT>5x the upper limit of normal (ULN); two
(0.9%) with peak ALT>10×ULN. Total bilirubin values
were within normal limits for both of these subjects
throughout the study. No patients in the chloroquine
group had ALT>5xULN. Post-treatment AST was>5×
ULN in one patient in the chloroquine group and>10×
ULN in one patient from the pyronaridine-artesunate
group; total bilirubin was within normal limits. Values for
AST and ALT were close to or within normal limits by
Day 28. No patient had peak ALT or AST>3×ULN plus
total bilirubin>2×ULN during the study.
Pyronaridine plus artesunate combination: paediatric
formulation
One study, conducted in Gabon, included children aged
two to 14 years old with the tablet formulation of fixed-
dose pyronaridine-artesunate at three different ratios 6:2,
9:3 and 12:4 mg/kg or a paediatric granule formulation
of fixed-dose pyronaridine-artesunate at 9:3 mg/kg; both
formulations were given once daily for three days [104].
In this study, between 70% and 90% of patients experi-
enced at least one adverse event, one third of which
(20–36%) was judged as being at least possibly study
drug related (Additional file 10). The majority of study
drug-related adverse events was observed in the category
of gastrointestinal disorders, including patients experien-
cing vomiting (n = 4), abdominal pain (n = 4), diarrhoea
(n = 1), and nausea (n = 1). Other possibly drug-related
adverse events were rare. No study drug-associated ab-
normal electrocardiographic finding occurred in this
clinical trial. All adverse events were of mild or moder-
ate intensity and there was no severe or life threatening
adverse events or increase in the rate of events based on
dose. Two serious adverse events occurred in the lowest
dose group (6 mg/kg pyronaridine + 2 mg/kg artesunate)
and were not study drug related. In this study there was
a modest decrease in median haemoglobin levels in the
first 72 h of treatment with complete recovery by Day 7.
A general rise in platelet count and eosinophils was
noted. There were no clinically significant changes in
the biochemistry parameters during the course of this
study.
Pyronaridine plus artesunate combination: pooled
analyses
In an integrated safety analysis of the pyronaridine-
artesunate Phase III studies, 57.2% of pyronaridine-
artesunate patients reported at least one adverse event
after baseline [120]. Pyronaridine-artesunate and the
comparator drugs were well tolerated. Overall, the rate
and type of adverse event were generally comparable be-
tween the various treatment groups and were of mild or
moderate severity. There were no deaths and few SAEs
(0.6% in pyronaridine-artesunate patients) and most of
them were not related to pyronaridine-artesunate. Over-
all, no changes in vital signs were observed except for a
fall in heart rate immediately after treatment, probably
reflecting the clearance of fever. The pattern of changes
seen in clinical laboratory parameters was consistent
with acute malaria and its resolution after treatment. All
biochemistry changes were transient and reversible and
not associated with any symptomatology. Pyronaridine-
artesunate was not associated with any increased risk of
haematologic adverse events.
The hepatic data were reviewed by an independent data
monitoring committee (IDMC) that consisted of six mem-
bers, including three international experts in Drug
Induced Liver Injury (DILI). The committee concluded
that a three-day treatment with pyronaridine-artesunate
can cause transient rises in ALT concentration in a small
subset of patients. However, the early onset (Day 3–7),
dose response trend, and rapid resolution were all consist-
ent with direct low-level toxicity. The IDMC commented
that with hepatotoxic drugs, serious idiosyncratic hepato-
toxicity typically begins after weeks or months of treat-
ment, like described with amodiaquine, another Mannich
base [126]. These findings, combined with the fact that
pyronaridine-artesunate is given for only three days, sug-
gest that the risk of progressive liver injury to subjects re-
ceiving pyronaridine-artesunate is very lowA detailed
review of ECGs from patients who received pyronaridine-
artesunate was conducted by a single, independent obser-
ver [127]. ECGs (n= 2,371) were reviewed from eight sites
in Asia and Africa in 477 adult patients (15–60 years,
mean age: 28 years) and 228 ECGs from one site in Africa
in 60 paediatric patients (two-14 years, mean age: six
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years). ECGs were assessed for waveforms (P, QRS and T
as well as the presence of U waves), rhythm (abnormal
rhythms as well as tachycardia and bradycardia) the evi-
dence of abnormalities of PR, QT, and ST segments and
ECG clinically significant abnormality. In the adult study,
only 2% of the total number of ECGs were considered
clinically significant abnormal, with no evidence of any
increased risk of QTc elongation and only 0.13% having a
QTc >450 msec (all of which were < 465 msec). There
were no differences with dose of pyronaridine-artesunate
and generally no changes from baseline with the exception
of bradycardia (HR<55 bpm), also being the most com-
monly reported finding; Day 1 (5.2%) and Day 2 (7.5%)
with similar frequency between Africa and Asia, being in
line with literature reports [128]. In those under 14 years
treated, the most frequent abnormality reported was sinus
arrhythmia, which is commonly reported in children of
this age. In summary the use of pyronaridine-artesunate
was not associated with either significant ECG changes or
increased risk of QTc prolongation.
Current status
Pyronaridine tetraphosphate-artesunate (PYRAMAXW) is
being co-developed by the Medicines for Malaria Venture
(MMV) and Shin Poong Pharm Co Ltd (Republic of
Korea) for the treatment of acute uncomplicated P. falcip-
arum and blood stage P. vivax malaria with a fixed-dose
combination tablet and granule formulation for paediatric
administration. MMV is a not-for-profit organization, op-
erating as a public−private partnership seeking to discover,
develop and deliver new anti-malarial drugs. A complete
suite of toxicology and safety pharmacology studies and a
full clinical programme has been undertaken. Pivotal
Phase III comparative clinical trials were completed in
2009, to include over 3,000 children, adolescents and
adults across sub-Saharan Africa and South East Asia in
more than 18 countries. Positive Opinion was received by
the European Medicines Agency under the Article 58 pro-
cedure in March 2012. Shin Poong received approval from
the Korean Federal Drug Agency in August 2011 and this
will be followed by national regulatory submissions and
WHO procedures.
Conclusion
Pyronaridine has shown value as a therapeutic partner
to use in artemisinin combination therapy. Pyronaridine
brings high efficacy, including against chloroquine and
amodiaquine-resistant strains, and the reassurance of
many years of successful use in China as monotherapy
and in combination with other anti-malarials, without
the development of widespread drug resistance. To date
no serious toxicities have been reported for pyronari-
dine.. Notably, pyronaridine in combination with artemi-
sinins appears to reduce the development of resistance
in vitro. Also, studies in vivo animal models indicate a
synergistic effect between pyronaridine and artemisinins
against parasites resistant to one or both components,
restoring efficacy against these strains. Consequently,
pyronaridine represents an ideal candidate for combin-
ation therapy with artemisinin derivatives, such as arte-
sunate. Pyronaridine also appears to be well tolerated in
clinical studies [57,74,104,107,111,120]. Clinical studies
of the combination of pyronaridine tetraphosphate and
artesunate are encouraging and show it to be a promis-
ing new artemisinin combination therapy for the treat-
ment of both P. falciparum and P. vivax malaria in
adult, children and infant populations [104,121].
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